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Arylhydrocarbon receptor activation promotes epidermal barrier formation and attenuates
Th2-cytokine dependent inflammatory processes: The biological basis of coal tar therapy in
atopic dermatitis
E Van den Bogaard,1 J Bergboer,1 M Vonk-Bergers,1 I Van Vlijmen-Willems,1 S Hato,3 P Van der
Valk,1 J Schroeder,4 I Joosten,2 P Zeeuwen1 and J Schalkwijk1 1 Dermatology, Radboud
University Nijmegen Medical Centre, Nijmegen, Netherlands, 2 Laboratory of Medical
Immunology, RUNMC, Nijmegen, Netherlands, 3 Tumor Immunology, RUNMC, Nijmegen,
Netherlands and 4 Dermatology, University Hospital of Schleswig-Holstein, Kiel, Germany
Coal tar therapy is the oldest treatment for atopic dermatitis (AD), a T helper 2 (Th2) mediated skin
disease characterized by epidermal barrier dysfunction associated with filaggrin loss-of-function
mutations. However, due to cosmetic aspects, suspected -albeit unproven- carcinogenicity and an
hitherto unknown molecular mechanism, coal tar therapy is progressively abandoned by derma-
tologists. The effect of coal tar on submerged and 3D cultured human keratinocytes, and in lesional
AD skin were studied by genetic (siRNA) and cell biological (gene/protein expression, protein
phosphorylation) analysis. Here we found coal tar to activate the arylhydrocarbon receptor (AhR)
signaling pathway, thereby inducing epidermal differentiation gene and protein expression result-
ing in accelerated epidermal differentiation. AhR knockdown abolished the coal tar-mediated induc-
tion of major epidermal barrier proteins, including filaggrin. Coal tar restored filaggrin haploinsuf-
ficiency and Th2 cytokine-mediated downregulation of terminal differentiation proteins. Furthermore,
coal tar reduced spongiosis and apoptosis, and downregulated the expression of eosinophilic
chemoattractant CCL26, all induced by Th2 cytokine signaling. These effects were mediated through
AhR-regulated STAT6 dephosphorylation, via activation of the nuclear factor-erytroid 2-related fac-
tor-2 (Nrf2) anti-oxidative stress pathway. This study not only provides a brand new perspective to
the oldest known drug in dermatological practice, it might also open a new avenue for pharma-
ceutical industries to reevaluate the AhR as a bona fide pharmacological target thereby enabling
the development of mechanism-based drugs for AD.
278 
IL-1beta as a therapeutic target in Epidermolysis bullosa simplex
V Wally,1 T Lettner,1 A Klausegger,1 S Hainzl,1 H Hintner2 and JW Bauer1 1 EB House Austria,
University Hospital Salzburg, Salzburg, Austria and 2 Department of Dermatology, University
Hospital Salzburg, Salzburg, Austria
Epidermolysis bullosa simplex type Dowling-Meara (EBS-DM) is a severe subtype of EBS which is
frequently caused by a heterozygous mutation in position 435 of the keratin 14 (K14) gene. This
dominant negative acting mutation leads to a self-aggregation of K14 filaments in the periphery of
the cytoplasm and to a subsequent collapse of the intermediate filament network, resulting in the
characteristic blistering and erosions of the skin after minor trauma. Expression profiling showed
that the inflammatory cytokine IL-1beta was significantly upregulated in K14 mutated patient ker-
atinocyte cell lines. Increased K14 expression levels were accompanied by a constitutive activation
of the JNK/MAPK-stress pathway. Here we show that EBS-DM specific overexpression of K14 pro-
tein and its subsequent aggregation was linked to increased levels of mature IL-1beta, which in turn
activated the JNK/MAPK pathway. This activation again led to increased expression levels of K14,
ending up in a positive feedback loop. We achieved a downregulation of K14 expression levels and
JNK phosphorylation by treatment with a neutralizing IL-1beta antibody and the IL-1beta inhibiting
small molecule diacerein. These preclinical data have formed the basis of a clinical pilot trial in
EBS-DM patients, which is currently ongoing.
279
Epidermal ablation of EGFR impairs skin immuno-homeostasis and epithelial differentiation:
implication in the pathogenesis of the rash in patients treated with anti EGFR drugs
F Mascia, C Keith, G Lam and SH Yuspa Laboratory of Cancer Biology and Genetics, NCI/NIH,
Bethesda, MD
The clinical use of several anti-EGFR agents revealed common adverse effects targeting skin and
skin adnexa. To gain insight into the etiology of these adverse effects, we developed an epidermally
targeted mouse model of EGFR ablation. EGFR was ablated in the epidermis in the litters derived
from Keratin5-driven Cre-Recombinase transgenics, crossed with EGFR floxed mice. The skin of
double transgenic mice reproduced the hallmarks of the skin lesions of patients undergoing
chemotherapy with anti-EGFR agents: infiltration of macrophages, mast cells, and lymphocytes fol-
lowed by formation of neutrophilic pustules. Epidermally ablated EGFR mice showed highly pru-
ritic and scaly skin with formation of keratin plugs and hair follicle destruction. Tissue samples iso-
lated from skin of double transgenics contained high mRNA levels of several inflammatory mediators.
Attempts to ameliorate or rescue the inflammatory phenotype by crossing double transgenics with
knockout mice for TNFR1/2, MyD-88, iNOS, CCR2 and Rag1 were unsuccessful indicating that
TNF-α, IL-1 family members, iNOS, CCL2 and lymphocytes were not primary drivers of the full
inflammatory phenotype. Immuno-histochemical analysis of skin cells isolated prior to the devel-
opment of the inflammatory phenotype showed enhanced F4/80 macrophage infiltration. Subcu-
taneous injection of clodronate liposomes into double transgenic mice reduced skin infiltrating
macrophages and mast cells, decreased overall inflammation, and lowered the expression of sev-
eral inflammatory mediators. Moreover, clodronate administration partially restored skin architec-
ture and differentiation by decreasing the expression of epidermal differentiation markers. Thus aber-
rant macrophage recruitment appears to have a primary role in the development of the lesions in
the EGFR ablated skin and can interfere with a proper differentiation program. These data highlight
the master role of epidermal EGFR in shaping immune cell driven inflammation and differentiation
in the skin.
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Combination of PLS3, Twist, CD158k/KIR3DL2 and NKp46 gene expression for the diagno-
sis of Sezary Syndrome
L Michel,1 F Jean-Louis,1 E Begue,1 C Ram-Wolff,2 M Bagot2 and A Bensussan1 1 UMR976,
Inserm, Univ. Paris Diderot, Sorbonne Paris Cité, Hôpital Saint-Louis, Paris, France and 2
Dermatology, APHP, Paris, France
Several molecular markers including T-plastin (PLS3), transcription factor Twist, CD158k/KIR3DL2
and NKp46 (CD335) have been specifically identified in patients with Sézary Syndrome (SS), the
erythrodermic and leukemic form of cutaneous T-cell lymphoma (CTCL). Our purpose was to inves-
tigate whether the expression profiling of these four genes by quantitative Real-time PCR (qRT-PCR)
can be employed for the diagnosis of SS. A cohort of 81 patients with SS was investigated for tumor
burden and mRNA expression quantification of PLS3, Twist, KIR3DL2, and NKp46, in CD4+-puri-
fied T cells from blood samples using SYBR Green qPCR and specific primer pairs. CD4+-purified
T cells from 12 healthy donors were studied as controls, with qRT-PCR mean values (±SD) of PLS3,
Twist, KIR3DL2, and NKp46 mRNA levels reaching 2.4±2.5, 6.6±8, 22.5±20.4, and 2.6±2.8, respec-
tively. A respective threshold of 95% significance was set up at 5, 10, 25 and 50, and any value less
than the respective threshold was considered as negative. As positive controls we used mRNA
mean levels (±SD) detected in SS HuT-78 cell line cultures (n=3) with 128±65 for PLS3, 13155±3000
for Twist, 316±40 for KIR3DL2, and 7.3±1.9 NKp46, respectively, as mRNA mean levels (±SD) in
NK-purified cells (n=3) reaching 0.4±0.1, 0.5±0.15, 684±80.3, and 371±80.2, respectively. Our
results demonstrated that qRT-PCR data accurately classified 100% of 81 SS patients with high blood
tumor burden. CD4+-purified T cells from SS patients expressed PLS3, Twist, KIR3DL2, and NKp46
mRNA mean levels (±SEM) of 706±133, 1440±292, 843±96, and 7.1±1.7, respectively. The accu-
racy was 100% in identifying these samples as SS patients since the four markers were detected in
20% CD4+-purified T cell samples, three ones in 53%, two ones 20% and only one marker (Twist,
PLS3 or Nkp46) in 7%. These results clearly demonstrate that gene expression profiling by quanti-
tative PCR on a selected number of 4 critical genes can be employed for the molecular diagnostic
of SS.
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Multicolor luciferase reporter gene assay system for IL-1β, 2, 8 and IFN-γ presents a novel
tool to evaluate immunological effects of drugs and their efficacy
Y Kimura,1 Y Ohmiya2 and S Aiba1 1 Dermatology, Tohoku University Graduate School of
Medicine, Sendai, Japan and 2 Bioproduction Reserch Institute, AIST, Tsukuba, Japan
Various immunosuppressant drugs are widely used against immune-mediated skin diseases. How-
ever, the relative potency of each drug and the mechanism how to suppress immune response are
mostly unclear. In particular, it is difficult to determine whether each drug induces immunological
effects through its effects on T cells or antigen presenting cells. So, we established a luciferase reporter
gene assay system that can easily and briefly evaluate the effects of chemicals on T cells and mono-
cytes (Mos), respectively (Multi-ImmunoTox Assay; MITA). The system is composed of the follow-
ing two stable cell lines. #2H4 derived from Jurkat T cells is transfected with the vectors containing
SLG luciferase regulated by IL-2 promoter, SLO luciferase by IFN-γ promoter, and SLR luciferase by
G3PDH promoter. #142-7 derived from THP-1 monocytes is transfected with those containing SLG
regulated by IL-1β promoter, SLO by IL-8 promoter, and SLR by G3PDH promoter. We evaluated
various immunosuppressant drugs by this system. The results corresponded well to the previously
reported immunological effects of the following drugs on T cells and Mos. Namely cyclosporin A
(CyA) and tacrolimus (TRL) dramatically reduced IL-2 and IFN-γ transcription by #2H4, and signif-
icantly but weakly IL-8 transcription, or none of IL-1β transcription by #142-7. The potency of TRL
was ten times higher than that of CyA. On the other hand, dexamethasone significantly suppressed
the transcription of all 4 cytokines, although its effects on T cell cytokine was less potent than those
of CyA. Finally, we succeeded in demonstrating that two sulfonamide, diaminodiphenyl sulfone
(DDS) and sulfasalazine, whose immunological action is yet to be determined, significantly sup-
pressed the cytokine transcription by #2H4 and #142-7, and that sulfasalazine was more potent
than DDS. These data suggest that MITA can present a novel high-throughput approach to evaluate
immunological effects of various drugs and their efficacy.
282 
Novel rapid diagnostic tests in the management of severe drug hypersensitivity
ME Polak, G Belgi, C Pickard, E Healy, PS Friedmann and MR Ardern-Jones
Dermatopharmacology, Clinical and Experimental Sciences, Faculty of Medicine, University of
Southampton, Southampton, United Kingdom
Drug hypersensitivity reactions (DHR) are common and occasionally fatal. Dermatologists are often
the first to identify these potentially severe systemic reactions because of the early involvement of
the skin. Rapid intervention can halt or limit the progression of such immunologically mediated
reactions but usually involves cessation of all medications. Lymphocyte proliferation (LPA) is the
most widely utilised assay of drug hypersensitivity but is not routinely available. To investigate the
usefulness of ex vivo testing for determination of the culprit drug during acute DHR we compared
the LPA with an overnight assay for drug-specific IFN-γ and IL-4 release in 23 cases during an acute
reaction, 31 patients post-recovery and 14 control subjects without DHR. For each patient up to
five possible culprit drugs were identified from the ingestion chart by an experienced clinician. Reac-
tions to 61 drugs in total were examined, including antibiotics (60%) and anticonvulsants (16%).
All individuals clinically improved when the suspected culprit drugs were stopped. Healthy con-
trols showed negative drug-specific proliferation and cytokine release in contrast to individuals with
a confirmed sensitivity (p<0.0001) and the assays demonstrated a test specificity of 95.11% (LPA),
82.85% (IFN-γ) and 92% (IL-4). Combined measurement of drug-specific IFN-γ and IL-4 cytokines
was more sensitive than LPA (82% vs 26% in acute DHR, 65% vs 26% post-recovery). The results
of LPA and IFN-γ assays correlated well (r=0.7, P<0.0001). In contrast to LPA, drug ELISpots showed
positive responses despite concurrent immunosuppressive medication in the index case and also
when an immunomodulatory culprit drug was tested. In summary, these results demonstrate that
the use of assays for drug-specific IFN-γ and IL-4 release in combination with the LPA can aid the
diagnosis of drug hypersensitivity during the acute, as well as the post-recovery, phases of the reac-
tion.
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Enzymatic change of autoantibody glycosylation modulates FcγR expression and reverts path-
ogenic effects of autoantibodies already bound to their skin target
K Vafia,1 M Hirose,1 K Kalies,2 S Groth,1 J Westermann,2 D Zillikens,1 RJ Ludwig,1 M Collin3 and
E Schmidt1 1 Department of Dermatology, University of Luebeck, Luebeck, Germany, 2
Institute of Anatomy, University of Luebeck, Luebeck, Germany and 3 Department of Clinical
Science, Division of Infection Medicine, Lund University, Lund, Sweden
Glycosylation of the Fc fraction of IgG plays an important role in the interaction with Fcγ receptors
(FcγRs). EndoS, derived from Streptococcus pyogenes, exclusively hydrolyzes the glycan of IgG.
EnodS has previously been shown to reduce the binding of treated IgG to activating FcγRs whereas
the affinity to the inhibiting FcγRIIB was increased. However, the effect of EndoS on autoantibod-
ies that have already bound to their target antigens has not been shown yet. Here, we used differ-
ent experimental models of the subepidermal blistering autoimmune disease epidermolysis bullosa
acquisita characterized by autoantibodies against type VII collagen. EndoS significantly reduced
lesions in BALB/c mice when EndoS was co-injected with the pathogenic IgG. Importantly, EndoS
suppressed disease activity in the immunization-induced mouse model, closely mimicking the
patients’ situation, even when anti-collagen type VII antibodies had bound to the skin and lesions
had already developed. Elution of skin-bound anti-type VII collagen IgG after EndoS treatment
revealed hydrolysis of the glycan moiety. Furthermore, mRNA levels of the activating FcγRs of CD11c-
expressing cells in skin lesions were significantly decreased, while mRNA levels of the inhibitory
FcγRIIB were increased. Here, we described two novel effects of EndoS: (i) enzymatic glycan hydrol-
ysis may be effective in already tissue-bound pathogenic IgG and (ii) differentially modulates the
expression of FcγRs leading to an anti-inflammatory milieu and, subsequently, to reduced tissue
destruction. Enzymatic autoantibody glycan hydrolysis warrants exploration as a novel therapeutic
option in patients with autoantibody-mediated diseases.
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Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in
psoriasis
M Talamonti, M Galluzzo, E Botti, G Spallone, M Bavetta, M Teoli, S Chimenti and A Costanzo
Dermatology, University of Rome “Tor Vergata”, Rome, Italy
Genetic and environmental factors are involved in determining the appearance of psoriasis, many
studies have shown the high prevalence of the HLA-Cw6 allele in patients affected by moderate to
severe psoriasis suggesting a role for this allele in the immune system dysfunction associated with
psoriasis. Recently, the deletion of LCE3B and LCE3C genes (LCE3C_LCE3B-del), members of the
late cornified envelope (LCE) gene cluster, was significantly associated with risk of psoriasis, sug-
gesting that compromised skin barrier function may have a role in psoriasis susceptibility. Objec-
tive of the present study was to determine whether the presence of HLA-Cw6 allele or LCE3B_3C
gene deletion might influence response to the IL-12/23 blocking antibody ustekinumab. To this
aim, we have performed HLA-Cw6 haplotyping and assessed the presence of LCE3B and LCE3C
deletion in 40 patients affected by moderate to severe plaque psoriasis and treated with ustekinumab
for at least 52 weeks. We have evaluated if the response to ustekinumab was associated to the pres-
ence of the HLA-Cw0602 allele. Our data indicate a faster initial clinical response to ustekinumab
in Cw6 positive patients. At week 4 PASI 50 was reached by 80% of Cw6 positive patients and in
50% of Cw6 negative patients (p<0,01), while no difference was observed at week 12 and 24. When
considering the presence of LCE3B_C deletion, we haven’t observed any significant variation in
response to ustekinumab. Similar results were obtained when considering PASI75. Also we have
studied the a mutual influence between the presence or absence of the HLA-Cw6 allele and the
presence or absence of homozygous or heterozygous deletion of LCE3B and LCE3C finding no sig-
nificant association. Our results suggest that the immune system-related molecule Cw6 rather than
the skin barrier-related molecules LCE3B_C may influence response to the T-cell targeting agent
ustekinumab.
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Anti-IL-23p19 (MK-3222): effects on the hallmarks of inflammation in psoriasis
C Bangert,1 D Laimer,1 E Riedl,2 E Greisenegger,1 A Horowitz,3 D Xu,3 R Liu,3 M Morrison,3
G Stingl1 and T Kopp1 1 Department of Dermatology, DIAID, University of Vienna Medical
School, Vienna, Austria, 2 Department of Dermatology, DGD, University of Vienna Medical
School, Vienna, Austria and 3 Merck&Co., Inc., White House Station, NJ
IL-23 is a key driver of inflammation in psoriasis released by keratinocytes, DC and macrophages.
The present study assessed the safety, tolerability, pharmacokinetics and clinical efficacy of the
anti-IL-23p19 antibody MK-3222. Patients either received placebo or MK-3222 at doses of 3 or 10
mg/kg, respectively, at week 0, 4 and 8. To analyze the impact of MK-3222 on the cellular compo-
nents of the psoriatic skin, we subjected biopsies from a subset of patients (n=22) obtained before
dosing and at week 12 to detailed immunohistochemical analysis. Clinically, patients receiving MK-
3222 showed dose-related improvement of disease severity, as compared to placebo treatment, up
to 100 percent. Psoriatic lesions, when compared to non-lesional skin, were marked by increased
epidermal thickness, strong expression of Keratin 16 and Ki-67 in keratinocytes and increased CD31+
vessel density. The dermal inflammatory infiltrate in psoriatic lesions predominantly consisted of
CD3+, CD4+, CD8+ T cells and CD68+ leukocytes and, to a lesser extent, of BDCA-2+ pDC, CD11c+
mDC and CD15+ neutrophils. After treatment with MK-3222 the observed epidermal alterations in
lesional skin resolved and were comparable to non-lesional skin. Remarkably, a significant reduc-
tion of CD3+ T-cells, pDC, mDC, neutrophils and macrophages in the inflammatory infiltrate was
seen. However, the number of CD8+ T-cells as well as CD207+ LC was not affected. Importantly,
psoriatic skin contained a significant amount of p19+ target cells, which were completely abolished
after treatment with MK-3222. Our data shows that administration of MK-3222 in psoriatic patients
induces a marked reduction of cutaneous inflammation.The clinical and immunohistological improve-
ment observed strongly suggests that targeting of IL-23 by anti-p19 treatment controls downstream
inflammatory pathways important for disease development.
286
Therapeutic Potential of Oral L-Histidine in Atopic Dermatitis
CE Griffiths and NK Gibbs Dermatological Sciences, University of Manchester, Manchester
Academic Health Science Centre, Manchester, United Kingdom
The aetiology of atopic dermatitis (AD) has been linked to deficiencies in the epidermal barrier pro-
tein, filaggrin (FLG). In mammalian skin, L-histidine (HIS) is rapidly incorporated into FLG (‘HIS-
rich protein’) which aggregates keratin filaments in granular layer cells, ‘collapsing’ them to form
squames that are critical to skin barrier function. Subsequent FLG proteolysis releases HIS as an
important Natural Moisturising Factor (NMF). If fed a HIS-restricted diet, healthy subjects develop
an eczematous rash. We therefore hypothesised that oral HIS would augment both FLG processing
and NMF-mediated skin hydration, enhance skin barrier function and reduce AD severity. Adult
AD patients (European AD Diagnostic Criteria; n=24; 58% female; 19-34 yrs) with mild to severe
AD were recruited into a randomised, double-blind, placebo controlled, proof of concept (PoC)
study. After a 2 wk ‘wash-out’ (WO) period, subjects were supplied with either oral HIS or placebo
(erythritol) to be taken once-a-day with clinic visits after 4 and 8 wks. Oral HIS led to significant
improvements in AD disease severity as measured by the validated SCORing AD - SCORAD (34%
and 32% reduction from post-WO mean of 31.9; p<0.003) and Patient Oriented Eczema Measure
(POEM; 38% and 38% reduction from post-WO mean of 18.4; p<0.002) tools after 4 and 8 wks
treatment respectively. Trans-Epidermal Water Loss (TEWL) a measure of skin barrier function, was
also reduced by 19% and 17% after 4 and 8wks of HIS treatment although this did not reach sig-
nificance. There were no adverse events associated with oral HIST administration. Both the clini-
cian (SCORAD) and patient (POEM) scores in the PoC study indicate that oral HIS has significant
therapeutic potential in mild-severe, adult AD. The efficacy of oral HIS is similar to certain mid-
potency topical steroids and combined with its safety profile, suggests that it may be a safe, con-
venient, non-steroidal intervention suitable for potential chronic/prophylactic use in the manage-
ment of AD in all age groups.
284 
PC111: a monoclonal anti-Fas Ligand antibody for the treatment of pemphigus
R Lotti,1 A Marconi,2 D Katiuscia,1 F Truzzi,1 T Petrachi2 and C Pincelli2 1 Laboratory of
Cutaneous Biology, University of Modena and Reggio Emilia, Modena, Italy and 2 PinCell srl,
Modena, Italy
Pemphigus is a chronic autoimmune bullous disease of the skin and mucous membranes. It is an
orphan condition, as the only treatment consists of long-lasting use of systemic immunosuppres-
sors, that associate with severe side effects, potentially leading to patients’ death. Apoptosis is def-
initely involved in the pathomechanisms of pemphigus. Pemphigus autoantibodies (PVIgG) induce
the up-regulation of Fas ligand (FasL) mRNA in keratinocytes, and elevated levels of FasL are pres-
ent in pemphigus sera. We have shown that FasL cleaves desmoglein (dsg)-1 and-3 in keratinocytes,
thus causing acantholysis in vitro. By contrast, FasL siRNA treated keratinocytes are protected from
PVIgG-induced apoptosis and acantholysis. The aim of this study was to validate the use of the novel
anti-FasL antibody (Ab) PC111 in vivo as a new therapeutic tool for pemphigus. Using the “passive
transfer” pemphigus mouse model, we showed that PVIgG induced the increase of the FasL active
form, starting at 1hr after injection, with a peak at 3hrs in mouse keratinocytes. Mice were then
injected with PVIgG alone or in combination with anti-FasL Ab at different times. When anti-FasL
Ab was administered simultaneously or 2hrs before PVIgG, blisters continued to form. When anti-
FasL Ab was given 1hr after PVIgG, blisters were still visible, but smaller. When anti-FasL Ab was
administered 3hrs after PVIgG, when FasL levels are highest, no blister formation occurred. The
effect was confirmed by measuring the length of the histologic clefts. By using decreasing doses of
anti-FasL Ab 3hrs after PVIgG injection, we set the minimum effective dose at 10μg/mouse of anti-
FasL, as the dose that completely inhibits blister formation. Finally, we screened several anti-FasL-
producing hybridomas and found the human PTA-4018 as the most effective in cleaving dsgs. The
human anti-FasL Ab PC111 is now ready to enter the pre-clinical phases, and it will likely repre-
sent a novel tool to treat pemphigus by targeting a pathway downstream the PVIgG-antigen bind-
ing.
288 
The Effect of Systemic Therapies on Langerhans’ Cell Migration in Psoriasis
K Mellody,2 F Shaw,2 S Ogden,1 RJ Dearman,2 I Kimber2 and CE Griffiths1 1 Dermatological
Sciences, University of Manchester, Manchester, United Kingdom and 2 Faculty of Life
Sciences, University of Manchester, Manchester, United Kingdom
Epidermal Langerhans cells (LCs) act as sentinels of the immune system: they migrate from skin to
local lymph nodes to present antigen to T cells. In the steady state LCs promote immune tolerance,
whereas following challenge they initiate the adaptive immune response. We have shown previ-
ously that LC migration in vivo is impaired in the uninvolved skin of patients with early-onset pso-
riasis. Using a novel epidermal explant model, we investigated the effect of systemic therapies on
LC migration in uninvolved skin of psoriasis patients (onset <40y of age). We compared patients
who had responded well to either T-cell targeted therapies (ciclosporin, methotrexate); anti-cytokine
biologics (adalimumab, etanercept, ustekinumab), or fumaderm, with untreated patients and with
healthy controls. Epidermal sheets prepared from biopsies of sun-protected skin were cultured for
24 hours; stained with CD1a and LC counts performed. Langerhans cells migrated from explants of
all healthy controls (mean 19.6±3.1%); however in untreated patients there was little or no migra-
tion (mean 0.9±1.8%). Migration was impaired in patients who had responded to T-cell targeted
therapies (mean -2±4.4%). In contrast there was significant restoration of migration in patients who
had responded to anti-cytokine biologics and fumaderm (mean 17.7±3.9%). We hypothesized that
changes in availability of local factors within the epidermal environment may be responsible for
abrogation of LC migration in untreated psoriasis. We cultured epidermal explants from patients
using supernatants derived from the human keratinocyte cell line HaCaT. There was a significant
restoration of LC migration in explants cultured in conditioned medium (mean 23.0 ± 4.7%). These
data indicate that therapies which target key cytokines involved in the pathogenesis of psoriasis can
restore LC migration whereas T-cell targeted approaches do not. It is likely that local, keratinocyte-
derived factors may be responsible for the abrogation of LC migration in psoriasis.
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Fluorescence-navigated sentinel node mapping using indocyanine green: report of 50 cases
Y Fujisawa, Y Nakamura, J Furuta, Y Kawachi and F Otsuka Dermatology, University of Tsukuba,
Tsukuba, Japan
Background and objective: Although sentinel lymph node (SLN) biopsy combined use of radioiso-
tope (RI) and blue dye (BD) achieved a high detection rate, approximately 5% of melanomas with
negative SLNs develop nodal metastasis (false-negative SLN biopsy). We tested a new lymphatic
navigation method using indocyanine green fluorescence imaging (ICG) to detect such “occult”
SLNs. Methods: Fifty skin cancer patients received SLN biopsy with the following three methods:
RI (99Tc-tin colloid), BD (2% patent blue), and ICG (0.5% indocyanine green). All the tracers intra-
dermally injected at the same location. Lymph nodes detected by any of the three methods were
counted as SLNs. Results: ICG detected more SLNs in 14 out of the 50 cases (28%). The average
numbers of SLNs detected by ICG, RI, and BD were 2.17, 1.68, and 1.75, respectively. Interest-
ingly, ICG detected more SLNs in one basin, it also detected additional SLNs in other basins not
found by the other tracers. Conclusion: ICG detected SLNs more efficiently than the conventional
methods, and these “occult” SLNs may offer an explanation for some false-negative cases. We rec-
ommend using ICG in addition to a conventional method to reduce the risk of overlooking these
“occult” SLNs.
290
Analysis of tumor escape mechanisms in melanoma tissues
E Tjin,1 G Krebbers,1 K Meijlink,1 B van de Wiel,2 J Haanen,2 F Vyth-Dreese,2 C Melief3 and
R Luiten1 1 Dermatology, Academic Medical Center, Amsterdam, Netherlands, 2 Pathology,
Immunology, Clinical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands
and 3 Immunohematology and Blood Transfusion, LUMC, Leiden, Netherlands
We recently reported that tumor escape mechanisms inversely correlated with the functional acti-
vation of melanoma-reactive T cell responses. Therefore, insight in these mechanisms is relevant for
the potential outcome of immunotherapy. We retrospectively investigated metastatic melanoma tis-
sues of patients before and after receiving autologous GM-CSF-producing tumor cells vaccines, for
the expression of tumor escape mechanisms in relation to the clinical outcome. Tumor tissues of 62
metastatic melanoma patients were analyzed by immunohistochemistry for the presence of infil-
trating (suppressive) cells (e.g.T cells, mast cells, regulatory T cells), T cell inhibitory factors (galectins,
PD-1/PDL-1), cytotoxic molecule granzyme B and tolerogenic cytokines (TNFa, IL-10). Data were
analyzed by scoring the percentage of tumor cells or infiltrating cells expressing the markers. Results
were related to (progression-free) survival (PFS and OS). Higher numbers of infiltrating T cells were
found in the tumor of melanoma patients with prolonged PFS (n=6; median PFS> 6 months; median
OS=43 months) compared to patients without PFS (n=10; median OS=15,4 months). Moreover,
more granzyme B+ CTLs were present in the tumor of the patients with prolonged PFS, coinciding
with prominent active caspase-3 expression in the tumor area, suggesting apoptosis of melanoma
cells induced by CTLs. Interestingly, patients without prolonged PFS had significantly higher expres-
sion of IL-10 and TNFa in the tumor cells, indicating a tumor environment suppressive for immune
cells. Our data show that advanced melanoma patients with prolonged PFS had increased numbers
of intratumoral CTLs, corresponding with apoptosis of melanoma cells. Together with low expres-
sion of IL-10 and TNFa in the tumor, this might contribute to the anti-melanoma immune response
in these patients, resulting in prolonged PFS. Currently, these results are related to the functional T
cell responses.
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CD203c expression-based basophil activation test is useful in the diagnosis of wheat-depend-
ent exercise-induced anaphylaxis
Y Chinuki,1 S Kaneko,1 I Dekio,1 H Takahashi,1 R Tokuda,2 M Nagao,2 T Fujisawa2 and E Morita1
1 Department of Dermatology, Shimane University Faculty of Medicine, Izumo, Japan and 2
Institute for Clinical Research, Mie National Hospital, Mie, Japan
Wheat-dependent exercise-induced anaphylaxis (WDEIA) is a special form of wheat allergy induced
by the combination of wheat ingestion and physical exercise. Wheat ω-5 gliadin is a major aller-
gen in conventional type of WDEIA and detection of serum IgE specific to recombinant ω-5 gliadin
is a reliable method for its diagnosis. Recently, increased incidence of a new WDEIA subtype caused
by hydrolyzed wheat protein (HWP) has been observed. We have encountered several WDEIA
patients who were sensitized to HWP primarily through percutaneous and/or rhinoconjunctival
routes by using HWP-containing facial soaps. A new subtype of WDEIA has little serum specific IgE
to ω-5 gliadin. To establish a predictive in vitro test for differentiating these 2 subtypes of WDEIA,
we measured basophil CD203c expression induced by different types of wheat proteins and eval-
uated the diagnostic efficiency of the reactions in the patients. We examined ten patients consist-
ing of five patients of new subtype and five patients of conventional type. Sensitization to wheat
proteins was confirmed by skin prick testing, detection of serum specific IgE, challenge testing, and
IgE-immunoblotting. Expression of CD203c on basophils was analyzed by flow cytometry using ω-
5 gliadin and HWP. HWP induced CD203c expression on basophils in all the patients of new sub-
type, whereas no significant CD203c expression in the patients of conventional type. ω-5 gliadin
induced CD203c expression in the patients of conventional type, but not in the patients of new
subtype. Measurement of CD203c expression on basophils is useful for evaluating differential sen-
sitization to wheat proteins in vitro according to the clinical condition in WDEIA. The basophil
activation test based on the expression of CD203c may help determine causative allergens for a
wide variety of food allergies.
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Antimicrobial Properties Of Distinctin In An Experimental Model Of MRSA-Infected Wounds
O Simonetti,1 O Cirioni,2 G Goteri,3 A Scaloni4 and A Offidani1 1 Department of Clinic and
Molecular Sciences, Dermatology, Ancona, Italy, 2 Department of Biomedical Sciences and
Public Health, Institute of Infectious Diseases and Public Health, Ancona, Italy, 3 Department
of Biomedical Sciences and Public Health, Institute of Pathology, Ancona, Italy and 4
Proteomics & Mass Spectrometry Laboratory, ISPAAM, National Research Council, Napoli,
Italy
The emergence of antibiotic-resistant Staphylococcus aureus strains is highly hindering the efficacy
of systematically administrated conventional antibiotics. Distinctin is a heterodimeric peptide from
the Amazonan frog Phyllomedusa distinct. Aim of the study was to evaluate the efficacy of dis-
tinctin in the management of cutaneous methicillin-resistant Staphylococcus aureus wound infec-
tions in an experimental mouse model. Wound, established through the panniculus carnosus of
BALB/c mice, was inoculated with colony-forming units of methicillin resistant Staphylococcus
aureus. Mice were treated with topical distinctin (1 mg/kg of body weight), topical teicoplanin (7
mg/kg of body weight), intraperitoneal teicoplanin (7 mg/kg of body weight); topical teicoplanin
and daily intraperitoneal teicoplanin; topical distinctin and daily intraperitoneal teicoplanin. Bac-
terial cultures of excised tissues and histological examination of micro-vessel density and of VEGF
expression were performed. The combination between topical distinctin and parenteral teicoplanin
showed to inhibit bacterial growth to levels comparable with those observed in uninfected ani-
mals. Wounded areas of animals treated with distinctin were characterized by a more mature gran-
ulation tissue with more organized and a denser type of connective tissue, compared to mice treated
only with teicoplanin . Treatment with topical distinctin resulted in a significant impact on VEGF
expression and micro-vessel density. In conlusion the combined use of distinctin with teicoplanin,
may be useful in the management of infected wounds through a significant bacterial growth inhi-
bition and an accelerated repair process.
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Loss of epidermal Langerhans cells caused by niacin deficiency: the pathogenesis of pellagra
as another member of trophic skin disorders
S Yamaguchi, K Taira, H Uezato and K Takahashi Dermatology, University of the Ryukyus,
Graduate School of Medicine, Okinawa, Japan
Deficiency dermatoses include acrodermatitis enteropathica, necrolytic migratory erythema and
pellagra. Acrodermatitis enteropathica is caused by Zinc deficiency, necrolytic migratory erythema
is most commonly caused by glucagonoma. Pellagra is caused by niacin deficiency and character-
ized by photosensitive dermatitis, diarrhea, dementia, however, the exact pathomechanism of
these symptoms is not yet known. From the histological resemblance of epidermal lesions of these
trophic diseases, we suspected the involvements of Langerhans cells in pellagra, whose loss is also
noted in acrodermatitis enteropathica recently. We examined the presence of various cells in the
skin lesion of patients with pellagra, and confirmed the disappearance of dendritic cells componens
by immunohistochemical staining for langerin, HLA-DR, CD1a and s-100. We show the degener-
ation of kerationcytes in the upper spinous layer due to apoptosis by TUNEL method and cleaved
caspase 3. We then analyzed the temporal change of the dendritic cells in the skin and pellagra
model mice, which are treated with 6-aminonictininamide. In these pellagra model mice, epider-
mal and dermal dendritic cells were almost completely lost after treatments. Pellagra model mice
and normal mice was treatment with 10% Benzalkonium chloride or 0.5%Dibutyl squarate on the
both sides ears. Swelling responses were quantified (ear thickness minus pretreatment ear thickness)
by using micrometer. Pellagra model mice showed the modestly decreased allergic response to 0.5%
Dibutyl squarate compared with normal mice, while the irritant response to 10% Benzalkonium
chloride was markedly prolonged in pellagra mice. Furthermore, the pellagra mice showed delayed
sunburn after the irradiation of 1J/cm2 UVB compared with normal mice. From the observations,
we supposed that losses of dendritic cells are the common and primary pathophysiological mech-
anism of the trophic skin diseased including pellagra.
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Induction of Th1 and Th17 cytokines in cultures of circulating CLA+ T cells and epidermal
psoriatic cells activated by streptococcus depends on MHC class II and MHC class I
M Ferran,1 ER Romeu,2 M Sagristà,1 AM Giménez-Arnau,1 A Celada,2 RM Pujol1 and
LF Santamaria-Babí2 1 Department of Dermatology. Hospital del Mar, Institut Municipal
Investigacio Mèdica, Barcelona, Spain and 2 Biomedical Research Institute, IRB, Department
of Physiology and Immunology. Barcelona University, Barcelona, Spain
Streptococcus pyogenes infection is associated with the onset of psoriasis; however the mechanisms
generating Th17 response and keratinocyte activation/proliferation under such circumstances are
poorly characterized due to the lack or relevant models. We have previously shown that ex vivo
activation of circulating CLA+ T cells and epidermal cells derived from autologous lesional skin with
streptococcus induces Th1/Th17 cytokine production together with epidermal cell activation and
hyperplasia, in contrast to CLA- from same patients and memory T cells from controls. Among
many other different mediators generated during this activation, we have analyzed by multiplex
fluorescence bead-based immunoassay IL-6, TNF-alpha, IL-17A, IL-17F and IFN-gamma in 5 days
supernatants from psoriatic patients. Under such activating conditions, novel basal keratinocytes
expressing CD29 and HLA-DR were generated analyzed by CFSE. The cytokines IL-17A, IL-7F, IFN-
gamma, IL-6, and TNF-alpha reached net values of 33 ± 13, 435 ± 242, 72 ± 49, 264 ± 295 and
4324 ± 1847 (pg/ml), respectively. The blockade of MHC class II or class I with specific antibodies
reduced the generation of novel basal keratinocytes and cytokine production by 90% and 50%,
respectively. Lymphocytes and keratinocytes from guttate psoriasis patients with onset associated
with pharyngeal streptococcus infection, ASO levels>200 and HLA-Cw6 tended to have a higher
stimulation ex vivo. Interestingly, cytokine production correlated with ASO levels r=0.7-0.9. Since
this model gathers some of the elements involved in the early plaque formation, we consider that
it could be useful to characterize and to identify initial mechanisms taking place during psoriatic
plaque formation.
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Downregulation of the Intracrine Skin Glucocorticoid Pathway in Psoriasis
R Hannen,1 S Rajpopat,3 R Cerio,2 J Burrin1 and M Philpott1 1 Centre for Cutaneous Research,
Queen Mary University of London, London, United Kingdom, 2 The Royal London Hospital,
London, United Kingdom and 3 Whipps Cross NHS Hospital, London, United Kingdom
Glucocorticoids (GC) induce powerful immune-modulatory effects and are used to treat inflam-
matory skin diseases including psoriasis. We previously demonstrated de novo cortisol synthesis in
normal primary human keratinocytes (NK). The purpose of this study was to examine whether the
local GC pathway is aberrant in psoriasis. Here we show that the GC pathway is downregulated in
human psoriatic skin. Expression of steroidogenic acute regulatory protein was decreased in both
lesional and uninvolved psoriatic skin. Thin layer chromatography showed reduced pregnenolone
to cortisol metabolism in primary psoriatic keratinocytes (PK) over 24h (38.8±6.1% NK vs. 8.7±0.4%
uninvolved and 8.6±0.2% lesion PK, P≤0.01). In addition, steroid sulphate levels in PK increased
(10.5±1.7% NK vs. 19.5±1.9% uninvolved and 22.8±3.0% lesion PK, P≤0.05), suggesting greater
steroid clearance from the system. LC-MS/MS analysis of cortisol release from whole skin mounts
over 24h was less than 10% in psoriatic samples relative to normal skin; normal skin
809.6±120.4ng/ml, psoriatic lesion 67.7±11.8ng/ml, psoriatic uninvolved 63.1±7.9ng/ml. Western
analysis of steroid enzymes was unable to detect 3bHSD1 expression in uninvolved and lesion
psoriatic epidermis but was expressed in normal skin. In addition immunohistochemistry revealed
glucocorticoid receptor (GR) expression was down regulated in lesion psoriatic skin but not unin-
volved or normal skin. We can now conclude that the local GC pathway from synthesis to GR expres-
sion is attenuated in psoriatic skin. Decreased GC synthesis and response in psoriatic skin would
provide an environment favourable for the promotion of inflammation that is well defined in pso-
riasis. Therefore dysregulation of localised skin GC pathway may be implicated in the pathogene-
sis of psoriasis. Better understanding of the local GC pathway represents a novel therapeutic target
and could limit the side effects that are associated with GC therapy.
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Extracorporeal photopheresis in chronic graft-versus-host disease
L Feci,1 P Rubegni,1 G Cevenini2 and M Fimiani1 1 Department of Clinical Medicine and
Immunological Sciences, Section of Dermatology, University of Siena, Siena, Italy and 2 Dpt.
of Cardiac Surgery and Biomedical Technology, University of Siena, Siena, Italy
Chronic graft-versus-host disease (cGvHD) remains a major complication of allogeneic hematopoi-
etic cell transplantation involving multiple sites and occurring in approximately 50% of transplant
recipients, with a significant negative impact on quality of life and patient survival. Extracoproreal
photochemotherapy (ECP) has been shown to ameliorate the signs and symptoms of patients with
cGvHD. The aim of the study was to test it on a subset of patients with moderate or severe cGvHD,
recalcitrant to traditional therapies, if ECP could have a role in long term control of the disease. 69
patients with moderate or severe recalcitrant cGvHD were treated with ECP for at least 2 years.
Cutaneous, oral and global disease activity was scored before each ECP cycle by means of National
Institutes of Health Criteria for Clinical Trials in cGvHD. Quality of life before treatment with ECP,
after 6, 12 and 24 months was scored by means Karnofsky Performance Scale Index (KPS). Our
data showed that ECP is an effective therapy in the treatment of cutaneous and oral cGvHD. More-
over, ECP allows to obtain a statistically significant improvement of the global score and therefore
of the quality of life. This latter finding is also demonstrated by statistically significant changed of
the KPS at 12 months. Our data also confirm that ECP may a have steroid-sparing effect in the treat-
ment of chronic GVHD. Only 7 patient were withdrawn from the study for unresponsiveness. No
clinical signs of immunosuppression or other severe adverse events became evident. Our study con-
firms the low risk of side effects and the long lasting anti inflammatory, immunomodulating effects
of ECP in patients with moderate or severe cGvHD. However multicenter controlled trials with a
standardized protocol are lacking which leads us to believe this treatment should be reserved for
patients with moderate or severe cGvHD, recalcitrant to traditional therapies.
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Interleukin-8 content in the stratum corneum is an good indicator of the severity of inflam-
mation in the lesions of atopic dermatitis
E Morita, T Amarbayasgalan and H Takahashi Department of Dermatology, Shimane University
Faculty of Medicine, Izumo, Japan
Atopic dermatitis (AD) is an inflammatory skin disease, characterized by both acute and chronic
eczema. Various markers are used to clinically evaluate the severity of AD. In order to identify a
marker of local severity of AD, we measured IL-8, IL-18, vascular endothelial growth factor (VEGF),
and transforming growth factor-α (TGF-α) levels in the stratum corneum (scIL-8, scIL-18, scVEGF,
and scTGF-α) and evaluated the correlation between the levels of these cytokines and the clinical
severity scores of localized skin lesions. Stratum corneum samples were collected from the skin
lesions of 50 patients with AD using the tape-stripping technique, and the scIL-8, scIL-18, scVEGF,
and scTGF-α levels were evaluated using the ELISA method. The levels of scIL-8, scIL-18, scVEGF,
and scTGF-α were significantly higher in patients with AD than in healthy controls. Additionally,
the levels of scIL-8, scIL-18, and scVEGF significantly correlated with the severity of AD. Among
these cytokines, scIL-8 showed the highest correlation with the severity scores of lesions in AD as
well as other parameters. Our results suggest that measuring cytokines in the stratum corneum by
using ELISA combined with tape stripping is a convenient method to evaluate the severity of skin
lesions in AD.
298
Localized scleroderma and ultraviolet A1 therapy: immunohistochemical analysis and role of
decorin
S Mei,1 M Pellegrino,1 C Peccianti,2 A Pianigiani,1 P Taddeucci,1 E Trovato,1 C Miracco,3 R Sirna2
and M Fimiani1 1 Unit of Dermatology Siena, Siena, Italy, 2 Unit of Dermatology Grosseto,
Grosseto, Italy and 3 Unit of Human Pathology and Oncology Siena, Siena, Italy
The objective of our study was to evaluate the effects of ultraviolet A1(UVA1) irradiation (340-400
nm) on decorin, a leucine rich proteoglycan (SLRP) with antifibrotic activity, in a group of patients
affected by localized scleroderma (LS). In particular, we considered the immunohistochemical expres-
sion of decorin before and after UVA1 therapy in order to evaluate if photo-induced modulation of
decorin exerts a key role in the progression of LS. Ten female patients with LS were treated with
medium-dose (50J/cm2) UVA1. In total, 30 treatments and 1500J/cm2 cumulative UVA1 doses were
performed in all patients. Clinical evaluation was performed using the modified Rodnan skin score
(MRSS). Skin thickness was also determined by 10MHz ultrasound examinaton. Moreover skin elas-
ticity, resilience, hysteresis and tensile distensibility were evaluated at baseline and after the treat-
ment with an elastometric valutation using Dermalab USB (Cortex Technology). All the measured
parameters showed an improvement after the therapy. Histological and immunohistochemical analy-
sis of skin were performed in all the patient at baseline and on completion of the course of UVA1
therapy. Immunohistochemical analysis was performed using a DSPG2 clone of decorin (Sigma
Aldright). Histological examination performed before and after the treatment showed a significant
reduction of the monocyte infiltrate and of vascular lesions with a substantial reduction of fibrosis,
especially in the reticular dermis where the collagen fiber bundles were more spaced. The immuno-
histochemical staining for decorin showed, after the treatment, an increased amount of the pro-
teoglycan, with a mild positivity in the papillary dermis, and a strong positivity in the reticular der-
mis with collagen fibers very similar in appearance to normal skin. Our results showed that UVA1
therapy has a positive effect in the fibrillogenesis of collagen and that decorin has a key role within
the same process.
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Alterations in dendritic cells subsets of psoriatic patients before and after biologic therapy
F Ricceri, L Pescitelli, L Tripo and F Prignano Division of Clinical, Preventive and Oncology
Dermatology, Department of Critical Care Medicine and Surgery, University of Florence,
Florence, Italy
Dendritic cells (Dcs) are focus of interest in psoriasis research. Previous studies showed that in the
inflamed dermis of psoriatic patients, there is an increase in DCs probably derived from circulating
precursors. To further investigate their role in pathogenesis of disease we analyzed peripheral DCs,
specifically myeloid DCs (mDCs) and plasmocytoid DCs (pDCs), in psoriatic patients treated with
anti-TNF-alpha therapy. Circulating mDCs and pDCs levels were evaluated by flow-cytometry in 8
patients (4 males and 4 females, age range 44-80) affected by moderate to severe psoriasis (PASI
score >10) before and after 6 months of infliximab therapy. In addition, 4 healthy blood (matched
with patients for sex and age) were included in the study. The mDCs and pDCs were identified by
the concurrent HLA-DR expression and mutually exclusive membrane expression of BDCA-1 or
BDCA-2, respectively. The expression of CD86 was also analyzed. Untreated psoriatic patients are
characterized by a quantitative deficit in their peripheral circulating mDCs (3.2 ± 0.3% of total PB
mononuclear in untreated psoriatic patients versus 6.8 ± 4.5% in the healthy control group - p<0.05)
and pDCs (1.3 ± 0.4% versus 2.3 ± 41.1%). Responders psoriatic patients (after 6 months of ther-
apy) showed a significant increase in their numbers of circulating mDCs (from 3.2% ± 0.3% to 7.8%
± 1.8% - p<0.05) and pDCs (from 1.3% ± 0.4% to 3.8% ± 2.7%). Our preliminary results, although
in a limited number of patients, suggest that in psoriasis peripheral blood was characterized by a
decreased number of both mDC and pDC subsets and an increased number after biological ther-
apy. According to our study this alteration in circulating DCs could correlate with the ongoing of
the disease and the response to biological therapy.
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Immunohistochemical Localization of Glucocorticoid Receptor Alpha and Beta in Inflam-
matory Dermatoses
M Kubin,1 K Haapasaari,2 T Hurskainen,1 K Tasanen,1 A Oikarinen1 and P Hägg1 1 Department
of Dermatology and Clinical Research Center, Oulu University Hospital, Oulu, Finland and 2
Department of Pathology, Oulu University, Oulu, Finland
Immunohistochemical localization of GRalpha and GRbeta has not previously been studied in
inflammatory dermatoses. Alternative splicing of glucocorticoid receptor (GR) pre-mRNA gener-
ates GRalpha, but also GRbeta, which does not bind glucocorticoids but antagonises the activity of
GRalpha in a concentration depended way. Ligand-free GRalpha receptor is located in the cyto-
plasm as a multi-protein complex, where it binds the hormones, translocates to the nucleus and
through binding to specific glucocorticoid response element (GRE) modulates the expression of glu-
cocorticoid-responsive genes. GRbeta can localize both in the cytoplasm and nucleus. GRbeta
mRNA has been found in a variety of human cells, but GRbeta protein has been shown to have a
more restricted cellular distribution, frequently it has been found in healthy T lymphocytes,
macrophages, neutrophils, eosinophils and endogenous peripheral mononuclear cells. 62 cases of
inflammatory dermatoses were selected from the files of pathological specimens (Department of
Pathology of Oulu University Hospital). All of the samples were stained with GRalpha and 60 of
the samples with GRbeta. Three cases of normal skin specimens were used as control samples. For-
malin-fixed, paraffin-embedded, 3-4 um thick sections were mounted on precoated slides and
immunohistochemically stained using Dako Real EnVision IHC -method. Commercially available
antibody was used for staining with GRalpha and GRbeta-specific polyclonal rabbit antibody raised
against human GRbeta was used for staining with GRbeta. As expected, staining for GRalpha was
mostly cytoplasmic and the signal was found in all cell types studied. As previously described,
GRbeta protein can be localized in both nucleus and cytoplasm. In these specimens staining was
mostly cytoplasmic, but especially neutrophil nuclei also stained widely positive. Our study describes
for the first time localization of GRalpha and GRbeta in inflammatory dermatoses.
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Epigallocatechin-3-gallate suppresses insulin-like growth factor-I-induced lipogenesis and
cytokine expression in SZ95 sebocytes
J Lee,1 M Im,1 S Kim,1 K Sohn,1 D Choi,1 Y Lee,1 Y Seo,1 C Kim1 and CC Zouboulis2 1
Dermatology, Chungnam National University Graduate Shcool of Medicine, Daejeon,
Republic of Korea and 2 Dermatology, Venereology, Allergology and Immunology, Dessau
Medical Center, Dessau, Germany
Acne vulgaris is the most common disease of the pilosebaceous unit. The pathogenesis of this inflam-
matory disease is complex, involving increased sebum production and perifollicular inflammation.
To identify effective agents for factors that induce acne vulgaris, we explored the pharmacological
potential of epigallocatechin-3-gallate (EGCG), which has been widely investigated as an anti-pro-
liferative and anti-inflammatory agent. In this study, we demonstrated that topical application of
EGCG to rabbit auricles reduced the size of the sebaceous glands. When applied to cultured human
SZ95 sebocytes, EGCG strongly suppressed cell proliferation and lipogenesis. These actions of EGCG
were reproduced in insulin-like growth factor (IGF)-I-differentiated SZ95 sebocytes. To investigate
the anti-inflammatory potential of EGCG, we evaluated pro-inflammatory cytokine synthesis in IGF-
I-differentiated SZ95 sebocytes and found that expression of IL-1, IL-6, and IL-8 was decreased.
These results provide early evidence that EGCG is an effective candidate for acne therapy whose
mechanisms of action in IGF-I-differentiated SZ95 sebocytes include the inhibition of lipogenesis
and inflammation.
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Adipose Tissue-Derived Mesenchymal Cells for the reparation of major facial traumatic defor-
mities
O Castana,1 V Alexaki,2 A Pallantzas,1 N Stampolidis,1 D Alexakis1 and E Castanas2 1 Plastic and
Reconstructive Surgery, General Hospital “o Evangelismos”, Athens, Greece and 2 Laboratory
of Experimental Endocrinology, University of Crete, School of Medicine, Heraklion, Greece
Purpose of the present work is to report the use of autologous adipose-derived mesenchymal cells
(ADMC) for the reparation of major posttraumatic facial defects. In recent years, a number of cells
resident in adult tissues have been characterized, isolated and used for tissue regeneration. Mes-
enchymal cells (MC) have a multitude of physiological roles: to differentiate or transdifferentiate into
multiple cell types, to modulate immune functions, and to participate in various effects. They can
migrate into injured or inflamed tissues, where they down-regulate the availability of proinflam-
matory cytokines and promote the survival of affected cells, while they produce a variety of growth
factors. Bone marrow is the classical tissue for the isolation of MC. Recently adipose tissue was rec-
ognized as an alternative source, providing a larger number of cells, being more easily accessible,
while limited liposuction is a less traumatic and painful procedure than bone marrow aspiration.
In the present study, we report the use of ADMC for the reconstitution of a patient with massive post-
traumatic hemifacial defect. A 42 years old man, after a major traumatic injury, was presented with
a loss of volume of the face, very thin skin and no mobility of the facial nerve, after the initial bone
and soft tissue reconstruction. In the impossibility to perform secondary reconstruction procedures,
we have applied ADMC, firstly a suspension of ADMC and isolated adipocytes and two months later
pure homologous ADMC. Clinical and laboratory assessment showed that there was a volume
restoration of the face, an amelioration of the thickness of the skin and, the major finding of our
study, an improvement of the mobility of the injured facial nerve. We propose local application of
homologous ADMC as a valuable alternative to other reconstructive methods of treatment.
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CD8+Tumor-infiltrating lymphocytes at primary site were the important prognostic factors
of cutaneous angiosarcoma
H Fujii,1 A Arakawa,2 D Utsumi,3 K Konishi,4 T Shiga,5 S Sano,5 K Takahashi,3 H Uezato,3
Y Miyachi1 and M Tanioka1 1 Dermatology, Kyoto University Graduate School of Medicine,
Kyoto, Japan, 2 Experimental Dermatology Unit, University of Lübeck, Lübeck, Germany, 3
Dermatology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan, 4
Dermatology, Kyoto City Hospital, Kyoto, Japan and 5 Dermatology, Kochi Medical School,
Kochi University, Nangoku, Japan
To investigate our hypothesis that the subsets of tumor-infiltrating lymphocytes (TILs) have a rela-
tion with the clinical stages or the prognosis of patients with angiosarcoma, immunohistochemical
analysis of TILs at all stages of cutaneous angiosarcoma was performed. Non-treated primary cuta-
neous anigosarcoma specimens from 36 patients at stage 1 with no metastases, 4 patients at stage
2 with lymph node metastases and 11 patients at stage 3 with distant metastases were evaluated
retrospectively by immunohistochemistry stained CD4, CD8, and FOXP3. Because the prognosis
and the numbers of TILs were different in each stage group, we evaluated TILs at each stage. Stage
1 patients with higher numbers of CD8+ TILs in their primary tumors demonstrated longer survival
compared with patients with lower ones, estimated by the Kaplan-Meier method and the log-rank
test based on the number of subsets of TILs. The higher numbers of CD8+ TILs had positive corre-
lation with the longer lung metastasis-free period. Moreover, the higher numbers of CD8+ TILs in
stage 3 patients had still positive correlation with their survival months. To compare the frequency
of CD8+ effector T cells with healthy controls and melanoma patients as a disease control, periph-
eral blood mononuclear cells (PBMC) were assessed by flow cytometry. Interestingly, the percent-
ages of CD8+ T cells producing IFN-γ in PBMC were significantly higher in angiosarcoma patients
compared with those of not only healthy controls but also melanoma patients. This study provides
the importance of CD8+ TILs at primary cutaneous lesions at each stage in the prognosis of patients
with angiosarcoma.
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Significance of ultrasound morphologic evaluation of basocellular cancers from the view-
point of the therapeutic modalities and followup procedures
K Szalai, Z Hatvani, A Artner, K Tóth, J Hársing and S Kárpáti Semmelweis University, Budapest,
Hungary
Introduction High frequency probes fine flow technique and tissue elastography are equally com-
pulsory elements int he diagnostic workup of cutan lesions. In the therapeutic planning process of
the most frequent cutan tumour namely the basaliomas the ultrasound morphology plays signifi-
cant role. Ultrasound characteristics which, beside its cardinal differential diagnostic role, also plays
an important role int he classification process of basaliomas. The ultrasonographic structure of
basaliomas shows typical specific picture that helps differenciate various histologic types during
thetherapeutic decision making. Patients and methods: 367 patients with basalioma were evalu-
ated with 18 MHz frequency linear transducer between 01 2010 and 05 2012. Depth of invasion,
dermal contour, vascularity and tissue elasticity of lesions were evaluated. Sonographical findings
were compared to histopathological findings. Above these criteria localisation, type, focality of the
lesion and patient age were analized, and based on that, the onko-board decided on the therapeutic
modality of choice to be the most effective for the patient. At most cases with superficial lesions
having sharp contour surgical excision was chosen, lesions of multifocal type or contour irregular-
ity on ultrasound or showing superficial spread pattern on pathology study were treated by surgery
combined with irradiation with providing onologists the correct status of the surgical borders,
chemotherapy was also offered to this population of patients.USG showed 97% correlation with
histologcal results. Nodular and infiltrative types of basaliomas were correctly predicted by US. Con-
clusions There was a statistically significant correlation between the histopathologic result and ultra-
sonographic morphology of the basaliomas in the examined patient population. The therapeutic
aproach based upon our method led to a small failure rate during the follow up period.
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Circulating endothelial cell levels in psoriatic patients before and after treatment with Etan-
ercept
G Caldarola,1 E Capoluongo,2 S Palumbo,2 A Maiorino,1 F Tassone1 and C De Simone1 1 derma-
tology, catholic university of the sacred heart, rome, Italy and 2 Institute of Biochemistry and
Clinical Biochemistry, catholic university of the sacred heart, rome, Italy
To explain the association between psoriasis and cardiovascular diseases, it has been supposed
that systemic inflammation of psoriasis may cause itself insulin resistance, which in turn triggers
endothelial cell dysfunction, leading to atherosclerosis and finally to myocardial infarction or stroke.
Circulating Endotelial Cells (CECs ) are cells shed from injured vessel wall as a consequence of
pathological processes causing a damage to the endothelium and their levels have been found to
be predictor of major cardiovascular events and death. Considering CECs as a possible marker of
endothelial damage/dysfunction, aim of this study was to evaluate their serum levels in psoriatic
patients, without any conditions already known to be associated with high CECs levels. CECs lev-
els were also measured before and after treatment with a TNF alpha blocking agent, etanercept, in
order to evaluate a possible effect of anti-TNF alpha treatment on endothelial wall. The CellSearch
system was used for the immunomagnetic isolation of CECs in the bloodstream. We enrolled 48
patients affected by psoriasis and 18 healthy subjects as controls. A higher count of CECs (in 4 ml)
was found in psoriatic patients than in healthy subjects (42,4 ± 37,9 vs 15,5 ± 4,4) (p= 0,009). A
significant reduction in CECs levels was observed after six months (13,8 ± 5,3) of therapy in 15 pso-
riatic patients who were treated with etanercept. These findings further sustain the hypothesis that
psoriasis is associated with an endothelial damage/dysfunction that could contribute to a high risk
of cardiovascular disease. Considering the reduction in CECs levels that with observed during the
treatment with etanercept, we can suppose that anti-TNF alpha agents exert a protective effect on
the vessel wall directly by interfering with the atherosclerotic process or indirectly trough a reduc-
tion of inflammation of psoriasis.
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Itch characteristics and its association with psoriatic patients’ quality of life
A Zalewska-Janowska,1 A Ograczyk,1 M Kozlowska,2 J Miniszewska,3 A Kepska1 and A Kaszuba2
1 Psychodermatology Department, Medical University of Lodz, Lodz, Poland, 2 Dermatology,
Paediatric Dermatology and Dermatooncology Department, Medical University of Lodz,
Lodz, Poland and 3 Psychology Institute, University of Lodz, Lodz, Poland
Current data indicate that itch is present in 70-90% psoriatic patients. The aim of the study was to
evaluate itch in relation with selected cytokine serum levels (IL-12, IL-23, IL-17a, TNF alfa), disease
severity and patients quality of life. 60 psoriatic patients (30 females, 30 males; age range: 20-70
years; mean+/-SD 44.91+/-14.78) and 48 healthy controls (21 females, 27 males; age range 19-50
years; mean+/-SD 31.38+/-9.01) took part in the study. Duration of the disease ranged from 3 months
to 54 years; mean+/- SD 18,76+/-13.50. Disease severity was evaluated by PASI Score and ranged
from 0.6 to 27.4 (mean+/-SD 9.32+/-5.97). Itch was estimated by Itch Severity Evaluation Ques-
tionnaire and ranged from 0 to 18 (mean+/-SD 7.0+/-4.47). There were used laboratory methods
(ELISA test) to assess cytokine serum levels and questionnaires to estimate quality of life – generic
SF-36 (Short Form-36, Health Survey) and dermatological method SKINDEX-29. All the obtained
results were analyzed statistically and the statistical significance was set at p<0.05. Comparing
cytokine serum levels (IL-12, IL-23, IL-17a, TNF alfa) their concentrations were statistically higher
in psoriatic patients than in the control group. There were also statistically significant differences
between females and males in QoL worse in women. There was observed the difference in IL–12
level – it was higher in women. Analyses revealed a relation between itch range, itch severity, con-
stant itch, global itch and higher cytokine IL-12 level. Itch correlated negatively with physical,
emotional and social functioning. In conclusion our study further points out at the importance of
assessment and management, and QoL in psoriasis patients.
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Insights into the function of etanercept in psoriasis: a study on slan (6-sulfo-LacNAc) express-
ing inflammatory dermal dendritic cells and their presumed precursors in blood
C Günther,1 K Blau,1 U Förster,2 A Viehweg,1 G Wozel1 and K Schäkel2 1 Department of
Dermatology, Technical University of Dresden, Dresden, Germany and 2 Department of
Dermatology, University Hospital Heidelberg, Heidelberg, Germany
Dermal dendritic cells (DCs) play a central role in the immunopathology of psoriasis. We previously
identified slan (6-sulfo LacNAc) DCs as proinflammatory DCs in human blood and as an inflam-
matory dermal DC subset in psoriasis. Blockade of TNFalpha by biologic agents is one of the most
powerful therapies for psoriasis. However, it is not known whether and how these biologics influ-
ence proinflammatory slanDCs. We therefore analysed slanDCs in skin and blood during a 24 week
treatment period of 10 patients suffering from psoriasis vulgaris with etanercept. In addition, the
effect of etanercept on slanDCs purified from blood of healthy donors was studied. SlanDC num-
bers being increased in active psoriasis skin lesions were significantly reduced in skin lesions after
4 weeks of treatment. In parallel we observed a reduction in the numbers of TNFalpha-, IL-23p19-
and CD11c- expressing cells in psoriatic skin. After 24 weeks of treatment the numbers of slanDCs
returned to that of healthy skin. However, the fraction of slanDCs expressing TNFalpha and IL-23p19
remained constant between 60 and 70% and the percentage of slanDCs among all dermal IL-23p19
positive cells even increased suggesting their sustained activation. This was supported by the lack
of significant costaining of slanDCs and the apoptosis marker active caspase3. With treatment the
percentage of slanDCs in blood increased from 0,9 to 2,8% of PBMC suggesting their reduced
recruitment to the skin. HLA-DR expression on slanDCs was reduced during treatment with etan-
ercept. In vitro etanercept efficiently downregulated the capacity of blood derived slanDCs to pro-
duce IL-1beta, IL-6, IL-23 and IL-12p70. This study for the first time documents the immunomodu-
latory potential of etanercept on a distinct and highly pro-inflammatory population of DCs in skin




Tazarotene cream in lamellar ichthyoses: a randomized, double-blind, vehicle-controlled and
dose-finding clinical study
T Ruzicka,1 S Emmert,2 C Bodemer,3 H Traupe,4 J Stalder,5 P Hoeger,6 J Lacour,7 U Blume-Peytavi,8
J Mazereeuw-Hautier9 and P Dupuy10 1 Departments of Dermatology, Ludwig-Maximilian-
University, Munich, Germany, 2 Georg-August-University, Göttingen, Germany, 3 Reference
Centre for Genodermatoses, Necker Hospital, René Descartes University, Paris, France, 4
Universitäts-Hautklinik, Münster, Germany, 5 Hôtel Dieu, Nantes, France, 6 Catholic Children
s Hospital Wilhelmstift, Hamburg, Germany, 7 L’Archet 2 Hospital, Nice, France, 8 Charité -
Universitätsmedizin, Berlin, Germany, 9 Purpan Hospital, Toulouse, France and 10 Orfagen,
Toulouse, France
There is a medical need for an effective and safe therapy of autosomal recessive congenital ichthyoses
(ARCI). Thirty (30) patients with ARCI were enrolled in a prospective, randomized, double-blind,
comparative and multicentric study. An intra-individual design (left vs right) was performed in which
patients were requested to apply either Tazarotene 0.05% or Tazarotene 0.1% cream on one side,
and their vehicle on the other side, once a day for 4 weeks. A treatment-free period of 8 weeks fol-
lowed. At each visit, the severity of the scales, as illustrated by a photograder, and roughness on
each side was independently assessed, according to a 4-point scale. All patients had lesions of mod-
erate (score 2) or severe (3) intensity for each parameter at baseline. Treatment response, as defined
as a remission of the two parameters (0 to 1) associated with a reduction of the score for scaling of
at least 2 points at the end of treatment, was observed in 6 patients under Tazarotene 0.05% (N=15,
40%), 8 patients under Tazarotene 0.1% (N=15, 53%) and 3 patients under vehicle (N=30, 10%).
Responses in both active groups were found to be statistically significant compared to the vehicle
group (p < 0.03), and non significant between themselves. Time-to-relapse occurred between 4 and
8 weeks after treatment in the majority of cases (no statistical significance between groups). Adverse
drug reactions were all local (skin irritation, skin erosions) and easily resolved by reducing the fre-
quency of product application. In conclusion, Tazarotene cream was demonstrated to be efficacious
and safe in patients with ARCI.
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Enhanced topical delivery of stem cell derived growth factors by elctroporation, fractional
laser and microneedle fractional radiofrequency
H Lee and S Lee Department of dermatology, CHA Bundang Medical Center, CHA University,
Seongnam-si, Republic of Korea
The use of growth factors in skin rejuvenation is emerging as a novel anti-aging treatment. How-
ever, it is well documented that hydrophilic molecules larger than 500 Dalton (Da) molecular weight
have very low penetration through the stratum corneum. Most growth factors are large hydrophilic
molecules greater than 20 kDa molecular weight; thus, penetration through the epidermis is an
important matter to apply them for skin rejuvenation. In this study, we conducted electroporation,
fractional CO2 laser, and microneedle fractional radiofrequency (RF) to enhance skin penetration
of stem cell conditioned medium. To confirm transdermal absorption and compare the effect of each
procedure and treatment parameter on the permeation enhancement, proteins in stem cell condi-
tioned medium were labeled with fluorescent dye, and were applied on the female miniature pig
skin after each procedure. Histologic changes by stem cell conditioned medium through microchan-
nels, which were produced by fractional laser and RF, were also investigated in photo-damaged
skin. As a result, fractional CO2 laser and fractional RF significantly increased the cumulative amounts
of proteins in stem cell conditioned medium both in epidermis and dermis. The amounts of pro-
tein-fluorescent dye conjugates were mainly affected by the depth of microporation, which was
dependent on the fluence of fractional laser and needle depth of fractional RF. Penetration after elec-
troporation was confined to the upper spinous layer of epidermis. Histologic examination after
stem cell conditioned medium and fractional RF revealed marked increase in dermal thickness, der-
mal collagen content, and dermal fibrillin-1 content. In conclusion, fractional laser and RF micro-
poration enhances the topical delivery of growth factors with high molecular weight. Thus, this tech-
nology can effectively improve photo-induced wrinkle formation by enhancing topical delivery of
active agents.
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Stress evaluation in adult patients with atopic dermatitis using salivaly cortisol
M Furuichi,1 M Yamaguchi,2 C Ueda,1 T Yamakoshi,1 T Makino1 and T Shimizu1 1 Department of
Dermatology, Graduate School of Medicine and Pharmaceutical Sciences, University of
Toyama, Toyama, Japan and 2 Graduate School of Engineering, Iwate University, Morioka,
Japan
Atopic dermatitis (AD) is a common inflammatory skin disease with recurring episodes of itching
and a chronic relapsing course. The symptoms of AD are often aggravated by stress and AD can
also lead to psychological stress, such as social isolation, and discrimination. The evaluation of stress
biomarkers is helpful to control skin inflammation by a more proactive management in AD patients.
The salivary cortisol level is a psychological stressor and it is a better index of chronic stress. This
study, measured salivary samples for cortisol in patients with AD (n=25) and compared them with
healthy control subjects (n=42). AD patients were also evaluated for general disease severity using
the SCORingAD (SCORAD) score. The serum TARC level, serum total IgE level, serum lactate dehy-
drogenase (LDH) level, and peripheral blood eosinophil count were measured by laboratory tests.
The Skindex-16 was used as a skin disease-specific instrument. The results showed saliva cortisol
level was significantly increased in AD patients in comparison to healthy subjects (p<0.01). The sali-
vary cortisol level was significantly correlated with SCORAD (r = 0.42, p< 0.05). TARC and LDH
were positively correlated with SCORAD. However, no statistically significant correlations were
observed between salivary cortisol level and Skindex-16. Saliva sampling has the advantage of being
non-invasive, making multiple sampling easy and stress free. These results suggest that the saliva
cortisol level is a useful biomarker to evaluate the stress in AD patients.
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Beneficial Impact of Effective TNF-Alpha Inhibitor Treatment on the Arterial Intima-Media
Thickness in Psoriasis
H Jókai, M Marschalkó, J Szakonyi, O Kontár, K Szalay, S Kárpáti and P Holló Department of
Dermatovenerology and Oncodermatology, Semmelweis University, Budapest, Hungary
Carotid intima-media thickness is a reliable surrogate marker of early atherogenesis. Due to sys-
temic character of inflammation immune mediated inflammatory conditions have been associated
with increased susceptibility to enhanced atherosclerosis and manifest cardiovascular diseases. A
decreased risk of cardiovascular complications have been observed in rheumatoid arthritis follow-
ing long-term TNF-alpha inhibitor treatment. There are only few data on the efficacy of TNF-alpha
blockers in reducing carotid intima-media thickness in psoriatic arthritis. We aimed to evaluate the
role of TNF-alpha inhibitors in influencing arterial wall inflammation in severe psoriasis vulgaris.
Carotid and brachial intima-media thickness was measured by high-resolution B-mode ultra-
sonography in 13 severe psoriatic patients (median age: 40 years, mean initial PASI: 25,56) before
therapy and after 6-month-long treatment. Statistical significance of the difference between initial
and 6-month values was determined for all the observed arteries collectively as well as separately
in the carotid and brachial artery group. Therapy improved skin symptoms in all patients which was
clinical marker of antiinflammatory effect of the drugs. (mean 6-month PASI: 1,15; mean 95,5%
PASI improvement) A significant difference was detected between intima-media thickness values
measured before starting therapy and at the end of 6th month when involving all the followed arter-
ies. (p=0,000150) Similarly, initial and follow-up data differed significantly at individual analysis of
carotid (p=0,011032) and brachial (p=0,005652) arteries. We suggest that effective blockade of TNF-
alpha mediated inflammatory cascade may be beneficial in reducing arterial wall inflammation
and consequently the progression of atherosclerosis as well as high frequency of cardiovascular
events associated with severe psoriasis. Further prospective investigations with more patients and
a long-term follow-up period are necessary.
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Studies on severe adverse drug reactions from allopurinol
M Gonçalo,1 I Coutinho,1 J Martins,3 B Neves,4 A Silva,3 R Nunes,2 A Martinho,2 T Cruz3 and
C Lopes3 1 Dermatology, University Hospital, Coimbra, Portugal, 2 Centro de
Histocompatibilidade, University Hospital, Coimbra, Portugal, 3 Centre for Neuosciences,
Faculty of Pharmacy, Coimbra, Portugal and 4 Chemistry, Universidade de Aveiro, Aveiro,
Portugal
Among us allopurinol is the main cause of severe cutaneous adverse drug reactions (SCADR). To
understand their pathophysiology, we performed HLA typing and patch testing in patients, and in
vitro studies with THP-1 cells using allopurinol and its main metabolite oxypurinol. We studied 25
patients with SCARDs imputed to allopurinol, 3 Stevens-Johnson/toxic epidermal necrolysis, 18
DRESS and 4 maculopapular exanthema. Patch testing with allopurinol and oxypurinol at several
concentrations and vehicles was negative in all patients. HLA typing, performed by PCR-RSSO in
25 patients and 12 controls exposed to allopurinol with no adverse effects, revealed HLA-B*58.01
in 12 patients (48%) and 1 control (8.3%) for a prevalence of 1.96% in the normal population.
THP-1 cells were stimulated for 24 h with 0.75 mM allopurinol and 2.5 mM oxypurinol, concen-
trations that caused a maximum of 30% reduction in cell viability. The mRNA levels of CD40, CD83,
CD86, CCR7, IL-12p40, TNF-α, IL-1α, IL-8 and HMOX-1, evaluated by quantitative Real-time RT-
PCR, revealed a very significant increase in HMOX-1 and, particularly, IL-8, when comparing non-
stimulated to stimulated cells. IL-8 mRNA levels increased by 11 and 30 fold, respectively, for
allopurinol and oxypurinol. SCADRs induced by allopurinol are very probably T-cell mediated, in
analogy to those induced by other drugs, even though patch testing was negative. HLA B*5801 is
a predisposing factor, but with a lower relative risk than HLA B*5701 for abacavir. Allopurinol and
oxypurinol directly stimulate THP-1 cells, inducing genes dependent on Nfr2 oxidative pathway,
like IL-8 and HMOX-1, which are also activated by contact allergens. As for other drugs and con-
tact allergens, allopurinol may induce oxidative stress in antigen presenting cells, promoting their
activation and therefore initiating an adaptive immune response.
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Autologous fat tissue transfer for the reconstruction of face atrophy in Linear Scleroderma
N Stampolidis, T Argyrakos, I Stasinopoulos, P Kourakos, A Pallantzas, I Kalemikerakis,
G Karagkounis and O Castana Plastic and Reconstructive Surgery, General Hospital “o
Evangelismos”, Athens, Greece
The purpose of the study is to describe a simple minimal invasive procedure for the repair of the
loss of volume of the face and the improvement of the atrophic skin lesions in patients with scle-
roderma. Scleroderma literally means “hard skin.” It is an uncommon disorder of unknown origin
of the connective tissue characterized by inflammatory and fibrotic changes in the skin, blood ves-
sels and skeletal muscles. There are two major types of scleroderma -localized and systemic - and
each type has many subtypes. The prognosis is generally good. The diagnosis is based in the typi-
cal skin changes, the laboratory tests and the skin biopsy. We report the case of a 22-year-old female,
who admitted to our clinic with a bilateral band-like skin depression in the zygomato -parietal region
of the face due to incipient sclerodermia. Autologous fat transfer was performed. Fat tissue was taken
from the patient‘s lumbar area with a liposuction under local anaesthesia. The fat tissue has been
filtered through gauze and then inserted below the dermis of the affected areas of the face. The pro-
cedure has been repeated nine months later. The clinical assessment has been made every two
months. The results are very good in cosmetic and functional aspects without any complication.
Little regarding treatment is mentioned for linear scleroderma in the literature. The conservative
and surgical treatments which have been used till now have poor results. Autologous fat grafting is
a standard method for soft tissue augmentation and correction of depressed lesions and atrophy.
This procedure can be performed on an outpatient basis with local anesthesia. We propose autol-
ogous fat tissue transfer for the reconstruction of face atrophy in patients with linear scleroderma,
as a simple minimal invasive procedure, with low cost, very good in cosmetic and functional aspect,
with minimal donor-site morbidity and without any complications.
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Clinical characterization at onset of childhood psoriasis in Sweden – a population based study
J Lysell, P Nikamo, C Wahlgren and M Ståhle Karolinska Institutet, Medicine, Stockholm,
Sweden
Age at onset is a disease modifying factor in psoriasis. Genetic as well as clinical differences have
been shown in patients with onset in childhood compared with those with adult onset. A peak of
onset at puberty has been reported and the genetic background is strong in patients with adoles-
cent onset of disease. In addition to the genetic background, epidemiological factors may impact
the outcome of psoriasis and affect the clinical presentation. Epidemiological knowledge surrounding
childhood psoriasis is steadily increasing but data captured at onset is still unsatisfactory. Therefore
we have established a cohort of children (n=96) recruited within 12 months after onset of disease
before the age of 16 years (mean age 8.4 years, range 2 months to 15 years) for prospective follow-
up. In this cohort, plaque psoriasis was the most common phenotype (68%) which is in accordance
with previous studies of childhood psoriasis. As much as 89% of patients showed lesions in the scalp
and 46% had facial lesions. Nails were affected in 11% and joint involvement verified by a rheuma-
tologist was diagnosed in 7% of patients. A first degree relative with psoriasis was reported in 40%
of patients and a first or second degree relative in 59% of patients. A history of flexural eczema was
reported in 15% and a history of allergy or asthma in 23%. Thus flexural eczema and allergy/asthma
was fairly common in our cohort of children with psoriasis. None of the patients showed antibod-
ies to gluten and 15% were overweight at onset of psoriasis.
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Pluripotent stem cell derivatives for full reconstruction of melanized pluristratifed epidermis
C Baldeschi and G Lemaitre ISTEM, INSERM U861, evry, France
Human epidermis has been produced in vitro for decades using adult epidermal stem cells from
donors to provide cell therapy and industrial use in pharmaceutical and cosmetic applications. As
potential alternative, pluripotent stem cells, immortal and pluripotent, have attracted major inter-
est. However, available protocols do not allow producing melanocytes and keratinocytes capable
of forming a fully differentiated epidermis out of human pluripotent stem cells. We present here a
successful and robust protocol for that purpose, the success of which is based upon replication in
vitro of the successive ontogenetic stages leading to formation of the epidermis. This protocol of
differentiation generates first a homogenous population of keratinocytes and melanocytes with
high proliferative capacity. Once seeded on an artificial matrix and either grown in vitro or else
transplanted in immunodeficient mice, these cells form a melanised pluristratified epidermis that
exhibits normal human characteristics. This opens the path for use of pluripotent stem cell lines in
skin regenerative medicine and for industrial use.
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Dandruff is associated with changes in the density of Propionibacterium, Staphylococcus and
Malassezia populations
C Clavaud,1 I Mouyna,1 A Bar-Hen,2 C Bouchier,3 F Pouradier,4 E Charles,5 J Guillot,6 R Jourdain,5
L Breton5 and J Latgé1 1 Unité des Aspergillus, Institut pasteur, Paris, France, 2 MAP5, Univesité
Paris-descartes, Paris, France, 3 PF1, Institut Pasteur, Paris, France, 4 International General
Direction of Hair Metiers, L’Oréal R&I, Saint Ouen, France, 5 Advance Research, L’Oréal R&I,
Clichy, France and 6 UMR BIPAR, Ecopham, Ecole Nationale Vétérinaire d’Alfort, Maison-
Alfort, France
Dandruff is a scalp disorder occurring in about 17-50 % of human individuals depending on the
population scrutinized, characterized by an abnormal flaking of the scalp. Although the presence
of bacteria on the scalp has been known for a long time, previous reports have suggested that dan-
druff was only due to M. restricta and M. globosa with the exception of McGinley’s paper pub-
lished in 1976 who looked at the analysis of the bacterial and fungal communities on dandruff scalp.
This last study was only based on culture and haemacytometer quantification, and the species M.
restricta was not identified until 1996. In the present study, the diversity of bacterial and fungal com-
munities of 19 scalp surface associated with dandruff was investigated using cloning and sequenc-
ing of the conserved ribosomal unit regions (16S for bacterial and 28S-ITS for fungal). Three major
microbial species have been found in dandruff or non dandruff scalps: Propionibacterium acnes,
Staphylococcus epidermidis and Malassezia restricta. Phylogenetic analysis of 824 16S rDNA
sequences of S.epidermidis, 1005 sequences of P.acnes and 2000 ITS-28S rDNA sequences of
M.restricta showed the presence of various phylotypes. However, none of the fungal or bacterial
phylotypes were preferentially associated with dandruff since the same proportion of each phylo-
type was found in the dandruff and non dandruff groups. The three main species were further quan-
tified with specific TaqMan MGB probes. The present data showed that in contrast to other studies,
dandruff is not correlated to the higher incidence of one fungal species but rather to changes in the
proportion of fungal and bacterial species on the scalp.
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Fumaric esters improve psoriasis via different gene signalling pathways than etanercept
AJ Onderdijk,2 DM Balak,1 EM Baerveldt,1 EF Florencia,2 M Kant,2 EP Prens2 and HB Thio1 1
Dermatology, Erasmus University Medical Center, Rotterdam, Netherlands and 2
Immunology, Erasmus University Medical Center, Rotterdam, Netherlands
Fumaric acid esters (FAE) are an effective systemic oral treatment for psoriasis that is widely used
in Europe. However, the mechanism of action by which FAE improve psoriasis is largely unknown.
To identify involved pathways and mechanisms, Affymetrix gene arrays were used for analyzing
gene expression profiles in psoriatic lesional skin from FAE-treated patients. At baseline and at 12
weeks of FAE treatment, RNA was isolated from lesional skin biopsies from 5 responders (> PASI-
75 improvement) and 5 non-responders (< PASI-50). Gene expression was analyzed with Ingenu-
ity Pathway Analysis (IPA). The gene expression pathways affected by FAE treatment were com-
pared with pathways affected by etanercept (anti-TNFα) treatment (NCBI Gene Expression Omnibus
GSE11903). Comparison of gene expression profiles at baseline and at week 12 in responders to
FAE treatment revealed 169 probe sets differentially expressed (>2-fold change, adjusted P<0.05).
FAE treatment most significantly affected the canonical pathway ‘role of IL17A in psoriasis’, reduc-
ing the expression of CCL20, CXCL1, DEFB4, S100A8 and S100A9. Comparison of responders and
non-responders at week 12 revealed 471 differentially expressed probe sets, including SERPINB4
and DEFB4, which both showed >20 fold change upregulation in the non-responders. When com-
paring changes in gene expression of psoriasis-related molecules during FAE and etanercept treat-
ment, we noticed minimal overlap, limited to the upregulation of FRZB, KRT15, S100A8 and S100A9.
Despite similar clinical improvement, gene expression in lesional skin during FAE treatment shows
little overlap with the expression profile during etanercept treatment. Effective treatment of psoria-
sis with FAE is firmly linked to suppression of ‘the role of IL17A in psoriasis’. This is an obvious but
novel clinical mechanism of action of FAE in psoriasis.
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Cutaneous Manifestations of Helicobacter Cinaedi Infection
S Shimizu,1 D Inokuma,1 M Watanabe,1 T Sakai,2 S Yamamoto,2 K Tsuchiya1 and H Shimizu3 1
Dermatology, Sapporo City General Hospital, Sapporo, Japan, 2 Hematology, Sapporo City
General Hospital, Sapporo, Japan and 3 Dermatology, Hokkaido University Graduate School
of Medicine, Sapporo, Japan
Helicobacter cinaedi (H. cinaedi) is a Gram-negative spiral bacillus that inhabits the intestinal
tracts of mammals. It has been implicated as the cause of human gastroenteritis and bacteremia,
particularly in immunocompromised individuals. Although cellulitis is sometimes reported to accom-
pany infection by this pathogen, the cutaneous manifestations are poorly understood. To clarify the
characteristic cutaneous features associated with H. cinaedi infection, 47 cases of H. cinaedi bac-
teremia experienced at one hospital as nosocomial infection were retrospectively evaluated. 34%
(16 cases) of the H. cinaedi bacteremia patients showed cutaneous lesions. They all had sudden
onset of erythemas accompanied by high temperature. The most common cutaneous manifestations
of H. cinaedi bacteremia were found to be superficial cellulitis, which appear as painful erythemas
or infiltrated erythematous plaques on the extremities. This study demonstrates these skin lesions
can be an early clinical indicator of H. cinaedi bacteremia in the setting of nosocomial infection.
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Application of thiocyanate ion and peroxide as antimicrobial wound therapy
J Wille Bioderm Technologies, Inc, Chesterfield, NJ
Thiocyanate ion, a broad acting anti-bacterial agent, is catalytically converted to the active agent,
hypothiocyanate by transfer of oxygen from hydrogen peroxide donor to the thiocyanate ion accep-
tor. A mouth wash with hydrogen peroxide and thiocyanate ion is effective in reducing mouth
sores. Use of this modality to treat acute or chronic wounds has not been reported. Here we address
several critical issues: 1) cytotoxicity of thiocyanate ion and hydrogen peroxide on keratinocytes,
2) antimicrobial effectiveness on bacteria that infect wounds, and 3) the choice of salivary peroxi-
dase. A stock solution of 20mM potassium thiocyanate and 80mM hydrogen peroxide was freshly
prepared and diluted twenty-fold in to ice-cold phosphate-buffer solution. The latter working solu-
tion was applied for 24 hours to serum-free cultures of normal human keratinocytes prewashed with
ice-cold phosphate buffer immediately prior treatment. Control cultures received only the phos-
phate buffered solution. At the termination of the study, visual phase contrast microscopic obser-
vation showed no discernable difference between the test and controls. Further, standard cell count-
ing methods revealed no cytotoxic loss of cells in test treated over or above the controls.
Concentrations of thiocyanate for 24 hours up to 50mM were not toxic to keratinocytes. The in
vitro cytotoxicity of hydrogen peroxide on keratinocytes was also conducted. Hydrogen peroxide
in serum-free culture medium greater than 2mM inflicted minimal cell damage as seen by reduced
uptake of crystal violet stain. These data suggest that basal layer keratinocytes may require lower
hydrogen peroxide concentrations in the final formula. Antibacterial studies of the action of thio-
cyanate /hydrogen peroxide solutions were performed using standard microbiological agar plate
assay against Pseudomonas aeruginosa as a pathogen often found in pressure ulcers. A five to six
log reduction in number of P. aeruginosa was found. These studies confirm the feasibility of apply-
ing nontoxic concentrations of thiocyanate/hydrogen peroxide to treat infected cutaneous wounds.
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Safety and Efficacy of novel topical herb-based lotion (KAM-2306) to manage atopic der-
matitis secondary infections
S Rozenblat,1 Y Bomstein,1 Y Manor,1 S Moh,2 S Kim2 and D Jung2 1 Kamedis Ltd, Tel-Aviv, Israel
and 2 Bio-FD&C, Incheon, Democratic People’s Republic of Korea
Introduction: Atopic dermatitis (AD) is a common chronic inflammatory skin disease, character-
ized by eczematous lesions, xerosis and pruritus. In severe eczema secondary infections may pre-
dominate. The condition develops due to impaired skin barrier and altered immune reactivity. KAM-
2306 is a barrier-based topical lotion augmented with plant extracts that stimulate antimicrobial
peptide beta-defensin involved in innate immune defense. Purpose: To assess the safety/efficacy of
KAM-2306. Methods: A cohort of 50 AD subjects were recruited to an open-label, non-random-
ized, interventional study. Thirty subjects were treated with KAM-2306 and 20 subjects were treated
with Carrier Lotion for 21 days. The severity of AD was evaluated with SCORAD index at each visit
(days 0, 7, 14 and 21). Results: The SCORAD index steadily decreased throughout the study, reach-
ing 46% reduction at the final visit as compared to the baseline. All 6 intensity signs steadily decreased:
the most prominent effect was recorded for oozing, associated with secondary infections, with an
86% decrease at the final visit in 26 out of 28 patients (93%). Pruritus was reduced by 60% at the
final visit. In comparison to a Carrier Lotion, KAM-2306 demonstrated a stronger reduction in
SCORAD after 21 days of treatment, particularly in symptoms related to secondary infections. KAM-
2306 equally affected severe and mild/moderate AD patients, while effect of Carrier Lotion was
reduced in severe AD patients. No secondary infections developed during the trial, and no adverse
events were recorded. Conclusions: KAM-2306 is safe & effective for symptoms relief of mild/mod-
erate and severe AD. By providing a mechanical barrier, the lotion maintains a moist skin environ-
ment, protects the skin from additional irritation and facilitates the healing process. The addition of
herbal extracts stimulating beta-defensin expression, might reduce secondary infections symptoms
and further protect the skin, thus contributing to the restoration of skin barrier’s integrity.
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Novel Polymerase Chain Reaction Method for Detection of Cutaneous Human Papillomavirus
DNA
T Mitsuishi1 and T Sasagawa2 1 Dermatology, Tokyo Women’s Medical University Yachiyo
Medical Center, Yachiyo, Japan and 2 Obstetrics & Gynecology, Kanazawa Medical
University, Ishikawa, Japan
There was no simple method to identify the human papillomavirus (HPV) genotypes that cause cuta-
neous warts. A new polymerase chain reaction (PCR) method, called SK-PCR, was developed for
this purpose. This PCR amplifies 210–238 base pairs of L1 DNA of 17 HPV types (HPV-1a, -2a, -3,
-4, -7, -10, -27, -28, -29, -40, -57, -60, -63, -65, -77, -91, and -94), which are thought to cause var-
ious cutaneous warts, including common, flat, butcher’s, punctate, and pigmented warts. The method
is novel because the location of these primers is completely different from that of any previous PCR
method for HPV. The target sequences are specific to alpha-, gamma-, and mu-papillomaviruses
(PVs), but not to beta-PVs. Overall direct sequencing and restriction fragment length polymorphism
(RFLP) were used to determine the HPV genotypes. Fifty of samples of plantar warts were exam-
ined, and HPV-27 was identified in 22 warts, HPV-57 in 15 warts, and HPV-2a in 9 warts. These
PVs, which are alpha species 4, were the most common. HPV-4 and -65 (gamma-PVs) and HPV-1a
and -63 (mu-PVs) were detected in one case each. A single HPV type was identified in all of these
warts. This method appears to be useful for genotyping the HPVs causing cutaneous warts, and for
distinguishing between HPV-induced warts and warty lesions unrelated to HPV infection.
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Reflectance Confocal Microscopy: an effective tool for monitoring UVB phototherapy in
psoriasis
EA Wolberink, PE van Erp, RT de Boer- van Huizen, PC van de Kerkhof and MP Gerritsen
Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background: In vivo reflectance confocal microscopy (RCM) is a novel, non-invasive imaging tech-
nique which enables imaging of skin at a cellular resolution comparable to conventional microscopy.
Objectives: We performed a pilot study to evaluate RCM as a non-invasive tool for monitoring UVB
phototherapy in psoriasis. Methods: In six patients with psoriasis, lesional and non-lesional skin was
selected for RCM imaging using a standardized protocol. Well-known histological features of pso-
riasis were visualized: parakeratosis, acanthosis, agranulosis, papillomatosis, presence of epider-
mal inflammatory cells, increased number of papillary capillaries and increased capillary blood
flow. RCM imaging was performed before the first irradiation with UVB-phototherapy, after nine
irradiations, at clearance and 12 weeks after clearance. In four patients 4 mm punch biopsies were
obtained and hematoxylin-eosin stained. Additionally, immunohistochemical staining was performed
with monoclonal antibodies specific for CD31, CD3, Filaggrin, K16, Ki67 and CD1a for correla-
tion to RCM images. Results: There was a high correlation between clinical, RCM and histological
features. Normalization of RCM and histological features corresponded highly to clinical improve-
ment of psoriasis. Conclusions: This study is the first to establish the use of RCM as an effective tool
for non-invasive monitoring of UVB phototherapy in patients with psoriasis. Potentially, RCM could
be used in many other skin diseases for monitoring therapeutic response on a cellular level in a
clinical or research setting.
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Serum YKL-40 as a possible biomarker for psoriatic arthritis
K Yamanishi,1 Y Imai,1 S Aochi,3 K Iwatsuki3 and H Sano2 1 Department of Dermatology, Hyogo
College of Medicine, Nishinomiya, Japan, 2 Division of Rheumatology, Department of Internal
Medicine, Hyogo College of Medicine, Nishinomiya, Japan and 3 Department of
Dermatology, Okayama University Graduate School of Medicine, Dentistry and
Pharmaceutical Sciences, Okayama, Japan
YKL-40, also known as chitinase 3-like protein 1 (CHI3L1), is a chitinase-like protein which is lack-
ing chitinase activity. Clinically, increased serum levels of YKL-40 have been reported in conditions
with inflammation and/or tissue remodeling, such as rheumatoid arthritis, Crohn’s disease and can-
cers. We have recently found that serum levels of YKL-40 are increased in psoriasis vulgaris (PV)
and in generalized pustular psoriasis (GPP) and we proposed YKL-40 as a possible biomarker for
those psoriatic disorders. In the present study, serum levels of YKL-40 in PV and GPP were com-
pared with those in 18 cases with psoriatic arthritis (PsA), which were diagnosed based on the CAS-
PAR criteria. Serum levels of YKL-40 were significantly increased in those cases with PsA and the
mean YKL-40 concentration was higher than that in PV and was comparable with that in GPP. In 5
cases with PsA, the serum levels of YKL-40 were significantly improved by treatment with infliximab
or adalimumab. Thus, serum levels of YKL-40 may also be useful as a biomarker for the treatment
of PsA.
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Treatment algorithm of hidradenitis suppurativa / acne inversa
CC Zouboulis Departments of Dermatology, Venereology, Allergology and Immunology,
Dessau Medical Center, Dessau, Germany
Hidradenitis suppurativa / acne inversa (HS) is a chronic, recurrent, follicular skin disease usually
presenting after puberty and been potentially scaring. It manifests with painful, deeply localized,
inflammatory skin lesions that occur in apocrine gland-rich areas of the skin, most commonly in
the axillae and the inguinal and anogenital regions (Dessauer definition). The recognized trigger fac-
tors include smoking and obesity. The treatment of HS is often disappointing, and has a significant
negative impact on patients’ quality of life. Regarding stressfulness and reduction of life quality HS
ranks on the top among all dermatological diseases. There are no approved drugs for HS treatment.
According to empirical analyses of treatment measures only topical 1% clindamycin solution, the
oral systemic combination of clindamycin and rifampicin, the hormonal antiandrogen combina-
tion of ethinyl estradiol and cyproterone acetate, the biologics infliximab and adalimumab, and sur-
gery reached an evidence level 2 and a grade B recommendation. To accomplish a grade-relevant
treatment, the HS experts group of the German Dermatological Society (DDG) proposed the fol-
lowing treatment algorithm: Hurley’s grade I: Topical 1% clindamycin solution treatment followed
by systemic clindamycin 300 mg 2-3x/d (or minocycline 2x50 mg/d) and rifampicin 300 mg 2x/ d
p.o. for 4-12 weeks, with clindamycin 300-600 mg 2-3x/d administered i.v. during the first 5 days
of treatment. For women with signs of hyperandrogenism/ hyperandrogenemia oral antiandrogen
hormonal therapy with ethinylestradiol/cyproterone acetate (up to 100 mg/d) should be adminis-
tered. Hurley’s grade II: Like in grade I followed by limited excision of recurrent lesions (alterna-
tively ablation with the CO2 laser). Hurley’s grade III: Like in grade I followed either by wide exci-
sion or by infliximab infusion 5 mg/kg body weight once or twice (after one week) or adalimumab
(160 mg s.c. and 80 mg one week later if required) to reduce the lesional and perilesional inflam-
mation, followed by the wide excision of the involved area.
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Stimulating mitochondria activity in association with LED exhibits cumulative anti-aging ben-
efits
R Chabert,1 L Fouque-Parachini,2 G Oberto,1 L Restellini,1 S Pinacolo,1 G Bressier,1 N Garcia1 and
N Domloge1 1 Vincience, ISP Global Skin Research Center, Ashland Specialty Ingredients,
Sophia Antipolis, France and 2 centre de dermatologie, Nice, France
Light Emitted Diodes (LED) has been increasingly used in recent years as a potent physical anti aging
effect. It has been demonstrated, in vitro, that LED acts by stimulating cell mitochondrial organelles
and by up-regulating the cytochrome electron transport. In these studies, we were interested in find-
ing synergies between LED and compounds applied into the skin, in order to enhance LED anti
aging effect on skin. IV 10.005 and IV11.002 compounds, designed to stimulate respectively skin
Extra-Cellular Matrix (ECM) or mitochondrial activity, were evaluated in combination with LED.
Fibroblasts were exposed to 12J/cm2, twice a week, for one week. Biofunctionals were applied at
1% on fibroblasts, for 96 h for IV11.002 and 48 h for IV10.005. Although, the application of IV
10.005 biofunctional or LED, separately, significantly enhanced collagen1, collagen3 and fibronectin
expression. Surprisingly, the cumulative treatments of both did not reveal a significant synergy on
the modulation of these ECM proteins. In contrast, combining mitochondrial photomodulation and
biomodulation with IV11.002, showed an cumulative effect with an enhanced expression of these
ECM proteins. Consequently, in order to confirm these results, we performed a clinical double
blind study on 10 volunteers. Volunteers’ forearms were exposed twice a week during 28 days to
LED 40J/cm2, and treated once a day with a cream containing IV11.002 or placebo. Four weeks
later, in vivo confocal microscopy assessment and clinical self-evaluation demonstrated that the skin
where LED was combined with the cream containing IV11.002 showed an cumulative rejuvenat-
ing effect. These results confirm that mitochondrion is a key target of LED, and that LED skin anti-
aging benefits could be optimized by the association with topical application of biofunctionals that
target mitochondria.
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Analysis of cell proliferation activity in human cutaneous tumors derived from keratinocyte
by using immunohistochemistry-based Cell Cycle Detection (iCCD)
T Bito,1 E Yanagita,2 R Matsuoka,2 I Tomoo2 and C Nishigori1 1 Dermatology, Kobe University
Graduate School of Medicine, Kobe, Japan and 2 Diagnostic Pathology, Kobe University
Graduate School of Medicine, Kobe, Japan
Human cutaneous tumors derived from keratinocyte are supposed to occur with dysregulation of
cell cycle. P53 gene is a key regulator of cell cycle, and is known as a tumor suppressor gene. The
mutation of p53 gene is detected in majority of malignant cutaneous tumors derived from ker-
atinocyte such as squamous cell carcinoma (SCC) and Bowen’s disease (BD), and results in uncon-
trolled cellular proliferation of the tumors. However, no objective markers were developed for the
evaluation of dysregulation of cell cycle. We analyzed cell proliferation activity in seborrheic ker-
atosis (SK), actinic keratosis (AK), BD, and SCC by using a novel method, immunohistochemistry-
based Cell Cycle Detection (iCCD), which is a multiplex immunohistochemical method that can
simultaneously stain cells in the G1 and S/G2/M phases and those undergoing apoptosis with the
3 markers Cdt1, geminin, and gamma- H2AX. The results clearly indicate that most cells are in the
G1 phase in normal epidermis and SKs. In contrast, AKs, BDs, and SCCs show high frequency of
S/G2/M and apoptosis cells in the lesions, and also present distinct expression pattern of the mark-
ers from the adjacent skin, indicating the tumor margin. The present observations suggest that the
iCCD can be one of the useful tools to differentiate the cutaneous malignant tumors from benign
ones, and could be a practical method to decide the treatment plan for malignant cutaneous tumors.
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Intralesional Steroids and Keloid Disorder; Can They Make Keloids Worse?
M Tirgan Keloid Research Foundation, New York, NY
Introduction: Triamcinolone acetonide is widely used in treatment of keloids [1]. Patients’ percep-
tions of the efficacy of intralesional steroids is presented with attention to worsening of keloids in
17.7% of patients and low overall rate of efficacy. Materials and Methods: An IRB approved online
questionnaire was answered by unselected group of keloid patients[2]. From November 2011 to
May 26, 2012, 261 patients completed the survey and 147 reported prior treatment with intrale-
sional steroids. Results and Discussion: 65 (45.1%) patients reported 5 or less injections, 17 (11.8%)
patients had between 6-9 injections and 60 (41.7%) patients had more than 10 injections. 5 patients
could not recall number of injections. 2 patients (1.4%) reported cure of their keloids, 46 patients
(31.3%) reported improvements, 73 patients (49.7%) reported no improvements and 27 patients
(17.7%) reported worsening of their keloids Conclusion This study indicates that intralesional steroid
injections are effective in only one third of patients; and can cause worsening of keloids in about
17% of patients. Although steroid injections are commonly used to treat keloids, the response rates
to this treatment needs to be better defined. References: 1. Sexton GB, Local Injection of Triamci-
nolone Acetonide in the Management of Certain Skin Conditions, Preliminary Report, Can Med
Assoc J. 1960; 83(26): 1379–1381. 2. www.KeloidSuvey.com.
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Quality Of Life is Worse Among Rheumatologist-Diagnosed Psoriatic Arthritis Patients Than
Other Psoriasis Patients Seen in Dermatology Clinics: Results of the PREPARE Study
T Rosenbach,1 M Lahfa,2 L Skov,3 N Bakos,4 J Fuiman,5 D Alvarez,5 R Northington,5 E Bananis5 and
R Boggs5 1 Dermatology Clinic Rosenbach and Partner, Osnabrück, Germany, 2 Paul Sabatier
University, Toulouse, France, 3 Copenhagen University Hospital, Gentofte, Denmark, 4
Hetényi Géza Hospital, Szolnok, Hungary and 5 Pfizer Inc, Collegeville, PA
The objective was to quantify differences in Quality of Life (QoL) between Psoriatic Arthritis (PsA)
patients and psoriasis patients without arthritis seen in dermatology clinics in the PREPARE study
(NCT01147874). Patients with plaque psoriasis were enrolled from 34 dermatology clinics in North
America and Europe, regardless of psoriasis severity, joint symptoms or previous PsA diagnosis,
and were evaluated by rheumatologists for PsA. Patients completed the Health Assessment Ques-
tionnaire (HAQ, scored 0=best, 3=worst, minimal clinically important difference [MCID]=0.30), the
Dermatology Life Quality Index (DLQI, 0=no impairment, 30=worst impairment, MCID=5), the
EuroQoL (EQ-5D, 0=death, 1=perfect health, MCID=0.05) utility questions and the EQ-5D Visual
Analogue Scale (VAS, 0=worst health, 100=best health, MCID=5), and the Hospital Anxiety and
Depression Screening (HADS, 0=no symptoms, 21=severe). Out of 949 patients who completed the
study, 285 (30%) had PsA. PsA patients had statistically significant and clinically meaningfully worse
HAQ, EQ-5D and EQ-5D VAS than other psoriasis patients (0.65 vs. 0.26, 0.66 vs. 0.80, and 66.8
vs. 76.5, p<0.001 each). DLQI scores for PsA patients were statistically worse, but the difference
was not clinically meaningful (8.0 vs. 6.0, p<0.001). More patients with PsA had at least mild
symptoms of anxiety and depression relative to those without (anxiety, 44.0 vs. 33.2%; depression,
29.1 vs. 19.7%, respectively, p=0.002). In conclusion, among psoriasis patients in this screening
study, nearly one-third had PsA. PsA patients had worse QoL than plaque psoriasis patients. Der-
matologists are in a unique position to screen for PsA and to ensure that patients with symptoms of
PsA are evaluated by a rheumatologist and/or receive appropriate treatment for their joint disease.
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The PrecisePASI accurately reflects small changes of psoriasis disease activity
AG Kolios, LE French and AA Navarini Department of Dematology, University of Zurich,
Zurich, Switzerland
Introduction: The Psoriasis Area and Severity Index is the score of choice to grade severity of pso-
riasis and detect clinical changes over time. However, as our treatment options improve and patients’
expectations rise, the PASI scores often are in the range below 10. It has been repeatedly shown in
the range of 0-10, the PASI score is neither sensitive nor very reproducible. This is due to the low
resolution of the area classes of 0-6 that were originally used to enable calculation of the score by
hand. Here we sought to overcome this problem within the bounds of the original PASI. Methods:
The PrecisePASI grades erythema, scaling and infiltration with 0-4 in head/neck, trunk, arms and
legs. The area involvement however is registered in actual percentages instead of the area classes.
Congruent with the original PASI’s discontinuous area curve, each percent area below 10% is graded
0.2 points and 0.05 points above 10%. Each area score is then weighted and summed up as in the
PASI. Results The PrecisePASI has a linear increase while the PASI has a staircase-pattern when the
change in area involvement is continuously increased. Both scores meet at the endpoint-relevant
values of 10% and at the PASI area-class defining percentages 30, 50, 70 and above. 768 patients
were analysed with both PASI and PrecisePASI. In the region of BSA 2-10, the both scores matched
closely (mean 0.13 +/- 0.72), but in the region of BSA < 2%, the PASI was up to 4.76 higher than
the PrecisePASI, mean 0.94 (+/- 0.78). Above BSA 10% instead, the PASI was up to 6.08 lower than
the calculation with actual percentages (mean 1.12 +/- 1.10). Conclusion The PrecisePASI is an
advanced calculation but not adaptation of the original PASI score. It corrects the undesired inac-
curacies of the PASI in the lower BSA ranges, is backward compatible with the original PASI and is
a tool to use as an endpoint in trials aiming to detect differences in the lower ranges of BSA.
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The correlation between clinical diagnosis and punch biopsy in typing basal cell carcinoma
H Kreukels,1 E de Vries,2 K Munte,1 S Koljenovic3 and E de Haas1 1 Dermatology, Erasmus MC
University Medical Center Rotterdam, Rotterdam, Netherlands, 2 Public Health, Erasmus MC
University Medical Center Rotterdam, Rotterdam, Netherlands and 3 Pathology, Erasmus MC
University Medical Center Rotterdam, Rotterdam, Netherlands
Skin cancer is the most common of all malignancies and its incidence continues to rise. This rising
incidence leads to a substantial burden of disease in both patients and the health care system. To
be able to continue to provide sufficient care for all patients, different management strategies are
necessary. One is to explore the possibility of avoiding punch biopsy in diagnosis BCC (basal cell
carcinoma) and SCC (squamous cell carcinoma) by trusting in the clinical diagnosis. Our objective
was to investigate the correlation between clinical diagnosis and punch biopsy in diagnosing BCC
and SCC as well as the correlation between clinical diagnosis compared to punch biopsy in typing
BCC. 100 patients with 124 suspect lesions for BCC or SCC were included and underwent a 3 mm
punch biopsy. Furthermore a short medical questionnaire was completed by . Clinical diagnosis
was compared to histopathological diagnosis of punch biopsy. We included 100 patients with 124
clinically suspect lesions. PPV (positive predictive value) of clinical diagnosis for BCC was 56.3%,
in typing BCC for sBCC (superficial BCC) 43.8%, for nBCC (nodular BCC) 34.5% and for iBCC (infil-
trative BCC) 38.5%. PPV of clinical diagnosis for SCC was 23.8%. We found that 12.9% (N=16) of
all included lesions were underestimated of which 2 cases of clinical suspect sBCCs and 3 cases of
clinical suspect nBCCs appeared to be SCC. In contrast, 50.8% (N=63) were overestimated by clin-
ical diagnosis whereof 43.5% was not even malignant. However, 14 of the 32 clinical suspect sBCC,
were actually sBCC, 12 lesions were actinic keratoses and 3 were morbus Bowen (total 90.6%, N
= 29), all requiring the same therapy. Our results showed that passing puch biopsy in suspect nBCC
and iBCC would result in mistreatment.
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Unresponsiveness to etanercept: is there a common phenotipical profile of patients?
G Babino, M Esposito, A Giunta, A Mazzotta, M Ruzzetti, M Talamonti and S Chimenti
Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
Etanercept is a tumor necrosis factor-alpha antagonist whose efficacy and safety in the treatment of
psoriasis have been mainly proven. Nevertheless, few studies evaluate a prior or secondary inade-
quate response. Our study aimed to evaluate the unresponsiveness to etanercept in daily clinical
practice for the treatment of psoriasis to eventually outline a common phenotipical profile of patients.
Between June of 2003 and December of 2011 a total of 605 psoriatic patients underwent etaner-
cept in our center. We carried out a retrospective observational study that collected data on 33
patients, affected by moderate-to-severe plaque type psoriasis (24) and psoriatic arthritis (14), treated
continuously with etanercept 50 mg twice weekly for 12 weeks and subsequentely 50 mg once
weekly, or etanercept 50 mg weekly, respectively. The following variables were evaluated: patients’
morphologic characteristics, comorbidities, previous performed treatments, outcome of the psori-
asis area severity index (PASI) [PASI 50, PASI 75, and PASI 90] and joint pain. Unresponsiveness to
etanercept was evaluate by PASI score unimprovement from baseline. In particular, primary ineffi-
cacy was the proportion of patients not achieving a reduction in PASI score >50% at week 12 as
compared to baseline, on the contrary secondary inefficacy is the lost of these achievement during
the treatment. In our study, at baseline mean PASI score was 11.47 (range: 2-28.4). At week 12,
9/33 patients (27.27%) achieved a PASI reduction from baseline <50% (primary inefficacy), while
24/33 patients (72.73%) achieved a PASI reduction from baseline >50% and subsequently loosing
efficacy during etanercept therapy (secondary inefficacy). The mean treatment duration was 106.49
weeks (range: 12-240). Our study demonstrate that most of the patients obtain the response in the
short-term treatment with etanercept, although a decrease in efficacy is observed; meaning that
secondary inefficacy is more frequently observed than the primary one.
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A Maximal Use, Systemic Exposure Study to Assess the Safety, Tolerability, and Pharmacoki-
netic Profile of AN2728 Ointment, 2% in Subjects with Plaque Type Psoriasis
LT Zane,1 M Toledo-Bahena,2 L Liu,1 MH Hughes,1 S Chanda1 and M Van Syoc1 1 Anacor
Pharmaceuticals, Palo Alto, CA and 2 IMIC, Mexico City, Mexico
The objective of this multicenter, open label, pharmacokinetic (PK) study was to evaluate the sys-
temic exposure of AN2728 Ointment, 2% under maximal use conditions in subjects ≥15 y of age
with plaque type psoriasis involving ≥25% body surface area (BSA), excluding the scalp. AN2728
was applied to all non-scalp psoriatic skin twice daily for 8 days (except Days 1 and 8 when a sin-
gle morning dose was applied). Blood was drawn for PK analysis on Days 1 and 8, pre-dose sam-
ples on Days 2-8, and 24 h post-dose on Day 9. Urine samples were collected for PK analysis on
Days 1 and 8. Safety evaluations included adverse events (AEs), vital signs, safety labs and 12-lead
ECGs. Local tolerability symptoms of burning/stinging and pruritus were also assessed. The 33
enrolled patients had a mean age of 46 y and were 88% male. Baseline psoriasis involvement ranged
from 25% to 80% BSA (mean = 38%) and Physicians’ Global Assessment severity ranged from 2
(mild) to 5 (very severe) (mean = 3.3). No deaths, SAEs, or discontinuations due to AEs were reported
during the study. A total of 11 AEs were reported by 7 subjects. All AEs were mild (64%) or moder-
ate (36%); none was severe. Most (64%) AEs were unrelated or unlikely related to study drug. Mean
scores for burning/stinging and pruritus improved substantially from Baseline and remained stable
and low during treatment. AN2728 was rapidly absorbed with a median Tmax value of 1 h on Day
1 and 2 h on Day 8. Mean Day 1 Cmax and AUC(0-12) values were 167 ng/mL and 878 ng.h/mL,
respectively. Corresponding mean Day 8 values were 109 ng/mL and 748 ng.h/mL. Overall, plasma
exposure increased as the amount applied increased. There was no evidence of accumulation over
8 days of dosing. Steady-state was achieved within 3 to 4 days. No correlation was seen between
incidence of AEs and higher plasma exposure levels. Based on these results, AN2728 Ointment,
2% applied to very large areas of psoriatic skin appears to be safe and well tolerated.
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Change in the echogenicity of the dermis caused by change of hydration monitored using high
frequency ultrasound
KR Mlosek,1 S Malinowska,2 A Dzwigalowska3 and R Debowska3 1 Department of Diagnostic
Imaging, II Medical Faculty of the Medical University of Warsaw, Warsaw, Poland, 2 Life- beau-
ty –private partner, Grodzisk Mazowiecki, Poland and 3 Dr Irena Eris Centre for Science and
Research, Dr Irena Eris Cosmetic Laboratories, Warsaw, Poland
Hydration is one of the most important parameters in assessing the appearance and condition of
skin. So far, measurements of skin hydration were performed using tewameters or corneometers.
However, whereas several difficulties in performing such measurements, it is important to look for
other methods that would enable assessment of the skin hydration degree. The aim of this study was
to evaluate the use of high frequency ultrasound to determine the level of skin hydration based on
the echogenicity of the dermis. The sampling consisted of 27 women aged 20-67 years with dry
skin on the lower extremities. The women were subjected 14 days of therapy consisting of the use
of preparations for dry skin, ie cleansing gel and body butter. The following parameters were eval-
uated: thickness of the epidermis, dermis thickness, echogenicity of the dermis. In addition hydra-
tion, lubrication and transepidermal water loss (TEWL) were measured on the skin surface. As a
result of therapy skin’s appearance has improved. Change in the appearance of the skin resulted in
noticeable changes in ultrasonography image. There were statistically significant differences in the
echogenicity of the upper layer of the dermis. After the therapy echogenicity decreased. There were
no statistically significant differences in the echogenicity of the lower layer of the dermis and in the
thickness of the epidermis and dermis. In conclusion, high-frequency ultrasound enables to moni-
tor changes in the skin associated with water storage base on changes in the skin echogenicity.
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Profiles of patients with psoriasis associated with hepatitis C virus infection. A case control
study
S Imafuku and J Nakayama Dermatology, Fukuoka University, Fukuoka, Japan
Psoriasis is a chronic inflammatory skin disease with various complications such as arthritis, dia-
betes mellitus, and hypertension. Hepatitis C is a chronic infection of hepatitis C virus (HCV), even-
tually leading to liver cirrhosis and hepatocellular carcinoma. The association of psoriasis and HCV
has been reported but there have not been a detailed case control study yet. To outline the profiles
of HCV positive psoriatic patients, patients with diagnosis of psoriasis who visited Fukuoka Uni-
versity from 1991 to 2011 were sought in the database and their medical records were manually
checked for detailed information about history of hepatitis C, or serum anti-HCV antibody (Ab).
Anti-HCV Ab positive (HCV+) patients were compared to a control group (HCV-). There were 54
(7.5%) HCV+ patients among 717 psoriatic patients. HCV+ patients had stronger male predomi-
nance (male:female=44:10 vs control 438:225, p=0.023), later onset (median age, 55 vs control 41,
p<0.0001), lower body mass index (22.41 vs control 24.12, p=0.0126), more frequent association
of diabetes mellitus (DM+/-=16/31 vs control 102/464, p=0.0116). HCV infection preceded onset
of psoriasis decisively in 89%. Interferon therapy exacerbated 70% of pre-existing psoriasis, and
induced psoriasis de novo in 8 patients. Our observation revealed that HCV+ psoriatic patients have
less BMI and more diabetec than HCV- patients do. This is possibly because HCV infection causes
chronic inflammation and overproduces TNF-alpha, which induces psoriasis in some patients with
certain predisposition. HCV infection can be an inducing factor of late onset psoriasis.
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Decreased stratum corneum hydration in type 2 diabetes patients is affected by blood glu-
cose level, and a novel moisturizer containing physiologic lipid granules can improve barrier
homeostasis as well as dry skin in diabetic patients
N Yoon, D Kim, N Lee, S Park and E Choi Dermatology, Yonsei University Wonju College of
Medicine, Wonju, Republic of Korea
Type 2 diabetes mellitus (DM) induces many skin problems related to chronic impaired skin bar-
rier state. Recently, we reported that a long-standing hyperglycemia decreased stratum corneum(SC)
hydration and delayed skin barrier homeostasis in Otsuka Long-Evans Tokushima Fatty rats, which
correlated with HbA1c levels presenting recent blood glucose control. Also, in this animal model
decreased epidermal lipid synthesis accounted for decreased lamellar body(LB) production. There-
fore, we hypothesized that physiologic lipid granules including ceramide, fatty acids and choles-
terol to mimic LBs with multiple lamellar structures have superior affinity to diabetic skin; better
moisturizing effect. Patients with type 2 DM (n = 43, aged 40-86 years, HbA1c over 7) were recruited
and instructed to apply the moisturizers with or without physiologic lipid granules on each extrem-
ity separately for 4 weeks. Before and after application, SC hydration, basal transepidermal water
loss (TEWL) and barrier recovery rates were measured. Thirty-nine patients completed the study. SC
hydration was significantly decreased in higher HbA1c (over 8.5) group compared to lower group
and increased significantly by moisturizer with physiologic lipid granules in both groups. Basal
TEWL was not different between both groups and not changed by application. Barrier recovery
after tape stripping was significantly faster in moisturizer with physiologic lipid granules, but no dif-
ference between both HbA1c groups. There were no remarkable side effects related with moistur-
izer. In conclusion, SC hydration defining dry skin is much influenced by blood glucose control
(HbA1c level) in type 2 DM patients, which is significantly improved by a novel moisturizer con-
taining physiologic lipid granules.
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Comparison of the cutaneous inflammatory cell infiltrate in early and late-onset psoriasis
E Theodorakopoulou,1 LA Jamieson,2 L Motta,2 RB Warren1 and CE Griffiths1 1 Dermatology
Research Centre, The University of Manchester, Manchester, United Kingdom and 2
Dermatophathology, Salford Royal Hospital, Manchester, United Kingdom
In 1985, Henseler and Christophers classified psoriasis into early-onset (EOP) and late-onset (LOP).
Genetic and immunological differences exist between EOP and LOP; HLA-Cw*0602 allele occurs
more frequently (55-80%) in EOP than LOP (15-20%) and epidermal Langerhans’ cells migration
is different. To further investigate these differences, we assessed the histology and immune infiltrate
in involved (PP) and uninvolved (PN) skin of both types. 32 patients aged ≥50y were recruited; 17
EOP (14 male, mean age 58±9y; 3 female, mean age 59±9y) and 14 LOP (8 male, mean age 66±5y;
6 female, mean age 62±6y) with a mean age of onset of 21 ± 8y and 54 ± 8y respectively. Skin
biopsies were stained with H&E and antibodies against CD3, CD4 and CD8. Positive epidermal
cells were counted per field at 200X magnification. Dermal infiltrate was assessed using a semi-
quantitative (0-3) scale. A significantly higher count of epidermal CD3+ and CD4+ cells was noted
in PP of LOP as compared to EOP patients; mean epidermal CD3+ in LOP was 42.8 ± 13.3 vs 31.7
± 17.5 in EOP (p=0.05), mean epidermal CD4+ in LOP was 15.1 ± 6.2 vs 6.7 ± 4.6 in EOP (p=0.001).
There was no significant difference in epidermal CD8+ counts in PP between the groups; mean
CD8+ in EOP was 19.1±11.1 vs 15.8 ± 7.8 in LOP (p=0.33). The epidermal CD4+/CD8+ ratio of
1.3 in LOP was significantly higher compared to 0.5 for EOP (p=0.002). After correction for con-
founding variables, using linear regression, these remained statistically significant. No difference
was noted in epidermal CD3+, CD4+ and CD8+ counts in PN between EOP and LOP. Neither der-
mal CD3+, CD4+ and CD8+ counts nor H&E staining were significantly different in PP and PN of
both groups. The data indicate that EOP is characterized by a relative paucity of CD4+ cells and a
predominance of CD8+ cells in the epidermis whereas LOP is characterised by an epidermotropism
of CD4+ cells. Collectively, these data provide further evidence that EOP and LOP are different con-
ditions.
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Histological response due to biologics treatment in psoriatic plaques
Y Okubo, T Maeda, M Muro, Y Mitsuhashi and R Tsuboi Dermatology, Tokyo Medical
University, Tokyo, Japan
Psoriasis treatments by biologics, such as TNF- α inhibitors and anti-IL-12/23 p40 antibody, have
resulted in significant clinical benefits for patients. However, there are few reports about the mech-
anisms of biologics in lesional tissue. The aim of the present study is to evaluate the histological
changes after administration of adalimumab (Humira), a TNF- α inhibitor, or ustekinumab (Ste-
lara), anti-IL-12/23 p40 antibody in lesion of patients with plaque type psoriasis. Skin biopsy spec-
imen were analyzed before and after treatment at 1 and 3 months from 4 Japanese psoriasis patients
(three patients were treated by adalimumab and one patient was treated by ustekinumab) by hema-
toxylin and eosin (H&E) stain, immunohistochemistry and electron microscopy. The histological
changes were evaluated to correlate with the disease severity assessed by Psoriasis Area and Sever-
ity Index (PASI) score. The lesional skin showed decreased epidermal thickness, orthokeratosis and
decreased dermal inflammatory cells. Loricrin expression, a keratinocyte terminal differentiation
marker, was restored and keratin 17, an aberrant differentiation marker was decreased. CD3, CD4
and CD8+ T lymphocytes were decreased in dermis, as well as CD11c+ dermal myeloid dendritic
cells, and CD68+ and CD14+ macrophages. TNF+ cells were decreased, while IL-17A+ cells were
increased in 2 cases treated by adalimumab. Electron microscopy revealed keratohyalin granules
in stratum granulosum reappeared at 1 month. Biologics for psoriasis rapidly decreased dermal
immunocytes, and epidermis was restored to normal differentiation. Decreased TNF+ cells may be
a good marker of efficacies of biologics.
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Childhood Lichen Sclerosus is poorly recognised
M Lagerstedt,1 K Karvinen,1 M Joki-Erkkilä,2 R Huotari-Orava,2 E Snellman3 and S Sallinen2 1
Tampere University, Tampere, Finland, 2 Tampere University Hospital, Tampere, Finland and
3 Päijät-Häme Central Hospital, Lahti, Finland
Childhood lichen sclerosus (LS) is a relatively rare, autoimmune skin disease. We focused on accu-
racy of diagnosis and features of childhood LS patients treated at Tampere University hospital in
1982-2010. The study comprised a register study, and a questionnaire to the patients. A search was
performed in hospital patient record database using ICD codes for LS. All hits were reviewed. The
data was picked up from patient records using a structured protocol. The patients also received a
questionnaire dealing their symptoms and effect of LS on QoL. Altogether 45 children were treated
for LS at Tampere university hospital in that time period, 44 girls and one boy. We focused on girls.
The age at the onset of LS was mean 7.1 years (range 2-18), and only in some girls the disease was
burst out after their menarche. The delay from onset of the symptoms to diagnosis was mean 1.3
years (range 0-8). Our estimation on prevalence was 0.09%. The majority of patients (84 %) were
misdiagnosed or without diagnosis in the referring unit. A false suspicion of sexual abuse was
expressed in one referral, and two suspicions arouse at the university hospital. Further features
included another autoimmune disease in 6, Turner’s syndrome in 2, kidney disease in 2, LS in fam-
ily in 4. The majority were treated with topical corticosteroids, despite 8 developed architectural
vulval changes, but no malignancies. Of 15 responding to questionnaire 9 (60%) had no follow-
up, and 3/5 patients, who were asymptomatic in their final visit reported recurrence of symptoms.
Nine girls reported lowered QoL. The association of LS and other autoimmune diseases should be
recognized. The high prevalence of Turner’s syndrome raises a question of the influence of oestro-
gen. The association with kidney diseases requires further research. Long-term follow-up is needed,
because the cancer risk remains unsolved. Sexual abuse must also be considered, because LS may
occur at the site of trauma.
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A “healthy, low-calorie diet” session for the treatment of recalcitrant atopic dermatitis
H Kobayashi, H Tamiya, S Yanagihara, A Aoki, K Hoshi, A Naruse, C Tateishi, T Nakanishi,
D Tsuruta and M Ishii Department of Dermatology, Osaka City University Graduate School of
Medicine, Osaka, Japan
A substantial portion of atopic dermatitis (AD) patients treated with conventional therapies become
intractable to treatment after experiencing several cycles of recurrence. Among these cases, a spe-
cific group of AD patients are found to consume an excessive amount of n-6 fatty acids and/or sugar.
We have achieved good clinical outcomes in such patients by adding dietary instructions to con-
ventional therapies. When symptoms remain intractable in spite of usual treatment with topical
steroids and anti-histamines, the patients are advised to join a session we call, “Refresh in the hos-
pital!”, which is intended to help them avoid fatigue, while also teaching them how to consume a
healthy diet. SCORAD (SCORing Atopic Dermatitis) and QOL scores of seventy-seven patients (age:
4-75 (30±13, mean±SD); M:34, F:43) admitted (for two to 20 (9±4, mean±SD) days) for recalcitrant
AD from April 2008 to March 2012 were examined and compared with those of outpatients. Dur-
ing hospitalization, the adult patients consumed approximately 1600 kcal/day of rice, boiled veg-
etables/beans and seafood, similar to the “traditional Japanese diet” consumed in Japan until the
1960s. The SCORAD scores of the patients decreased significantly from 51±20 (mean±SD) to 17±12
after hospitalization and continued to decrease one month (20±14), three months (18±11) and three
years (17±10) after discharge. Although the scores of the outpatients measured at three years (16±16)
also decreased from baseline (46±20), the scores of the outpatients measured at one (33±21) and
three months (26±15) were significantly higher than those of the inpatients (p<0.01, 0.05). The QOL
scores of the inpatients also decreased significantly after hospitalization. For patients with recalci-
trant AD, hospitalization to experience a healthy diet with 30% fewer calories improves SCORAD
and QOL scores. Such behavioral/cognitive sessions may complement and improve the long-term
effects of standard medical therapies.
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A retrospective analysis of clinical and immunological parameters in pemphigus patients
M Behzad, S Grieshaber, A Jacobi, M Hertl and R Eming Department of Dermatology and
Allergology, Philipp University of Marburg, Marburg, Germany
Pemphigus is a potentially life-threatening blistering autoimmune disease remaining therapeutically
challenging. A commonly applied therapy consists of high-dose systemic corticosteroids in combi-
nation with immunosuppressive agents such as azathioprine or mycophenolate mofetil. In therapy-
resistant patients second line therapies such as immunoadsorption, the B-cell depleting anti-CD20-
antibody rituximab or high dose intravenous immunoglobulins are needed. In this retrospective
study we investigated the therapeutical response of first and second line treatment options on the
basis of clinical and immunological parameters of 20 pemphigus patients refractory to combined
systemic immunosuppressive therapy. The median observation period was 42 months [range: 6 to
72 months]. During this observation period, clinical activity quantified by the recently introduced
ABSIS score as well as immunological parameters such as anti-desmoglein 1 and 3 autoantibody
titers were determined regularly. Two patients received systemic immunosuppressive therapy only;
another 2 patients received adjuvant rituximab or immunoadsorption, respectively, while 14 patients
received immunoadsorption in combination with rituximab and 3 of those were treated addition-
ally with intravenous immunoglobulins. During the observation period, antibody titers correlated
well with the clinical activity in most of the cases. After a median observation period of 42 months,
11 of the 20 patients were in complete remission, 6 of them without any immunosuppressive treat-
ment. In 8 patients a partial remission has been achived and 1 patient still showed a high clinical
activity. Five patients relapsed after combined treatment with immunoadsorption and rituximab and
received another cycle of IA and Rtx again. The present findings show that in severe and refractory
pemphigus patients the standard therapy is often not sufficient. In these cases, with second line ther-
apies a long term control of the disease activity can often be achieved.
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Intermediate to long-term efficacy and safety of etanercept: report from the psoriasis reg-
istry Austria
M Inzinger, I Roschatt, W Weger, W Salmhofer and P Wolf Department of Dermatology, Medical
University Graz, Graz, Austria
More information is desirable on the anti-psoriatic long-term efficacy of biologics, including etan-
ercept. We analyzed available data on the clinical efficacy of etanercept in patients with chronic
plaque psoriasis treated under daily life conditions at the Department of Dermatology, Medical Uni-
versity of Graz, Austria. Data from the psoriasis registry Austria (http://www.psoriasisregistry.at) of
77 adult psoriasis patients (29 women and 48 men; median age, 49 years; age range, 15 to 79
years) with median disease duration of 19 years (range, 1 to 49 years) treated with etanercept between
2005 and 2012 were extracted for analysis. The efficacy endpoints of this retrospective study were
per-protocol complete remission (CR), PASI 90, PASI 75, and PASI 50 reduction. Seventy-two patients
completed 3 months of treatment, 70 completed 4 to 6 months, 60 completed 7 to 12 months, 44
completed 13 to 24 months, 33 completed 25 to 36 months, 20 completed 37 to 48 months, 7 com-
pleted 49 to 60 months, and 2 completed 61 to 72 months of therapy. Thirty-six of 77 (47%) patients
discontinued etanercept-treatment, including 9 (12%) due to lack of efficacy, 8 (10%) due to side
effects (2, injection site reactions; 2, soft tissue infection; and 4 others), 7 (9%) due to switch to
another treatment, 6 (8%) due to patient wish, 5 (6%) due to satisfactory therapeutic response (at
least PASI 75), and 1 (1%) due to malignancy (bladder cancer). The CR, PASI 90, PASI 75 and PASI
50 rates were 2%, 20%, 28% and 74% at month 3 (n, 46 patients); and 18%, 39%, 71% and 89%,
at month 6 (n, 38 patients), respectively. Intermediate to long-term follow-up of patients with ongo-
ing treatment of at least 6 months duration revealed that the CR, PASI 90, PASI 75 and PASI 50 rates
were 8%, 46%, 81% and 97% after a median time of 34 months (range, 6 to 76; n, 37 patients).
This analysis indicates that approximately 45 to 50% of psoriasis patients exhibit a favorable long-
term response to treatment with etanercept.
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Analysis allergic reactions in two patients with anaphylaxis induced by the ingestion of shi-
itake mushroom
K Ohko and M Ito Division of Dermatology, Niigata University Graduate School of Medical
and Dental Sciences, Niigata, Japan
Shiitake are popular edible mushrooms all over the world, and eating raw shiitake may lead to rel-
atively common ‘shiitake dermatitis’ or toxicodermia. There are few reports of immediate allergy
from shiitake mushroom. We report two cases of anaphylaxis that occurred immediately following
the ingestion or touching of shiitake mushroom. However shiitake mushroom allergen which has
so far been identified and characterized. The aim of our study was to analysis allergic reactions in
two patients with anaphylaxis induced by the ingestion of shiitake mushroom. The two patients were
42 year-old, female office worker (case 1) and 35 year-old, male shiitake grower (case 2). Serum
samples were collected from two patients. We examined serum IgE level in these patients. Next,
extracts from shiitake mushroom were analyzed by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE), Western blotting and mass spectrometry. The two patients have nor-
mal IgE levels (case 1: 32.4 IU/ml, case 2 : 136.0 IU/ml). Skin prick tests showed no positive reac-
tion, but scratch testing were strongly positive for shiitake extracts in both patients. Western blot-
ting revealed that the sera of both patients showed specific IgE binding to shiitake extracts, and no
binding to normal serum. In conclusion, shiitake may cause immediate IgE-mediated allergy that is
manifested in the skin as urticaria. This skin symptom is different from ‘shiitake dermatitis’ that is
caused by eating raw shiitake. Skin tests and immunoblot for immediate allergy and detection of
specific IgE are important when contact dermatitis from shiitake is investigated.
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Transdermal drug delivery facilitated using a combination of microneedles and a magne-
tophoretic patch
CJ Quirk1 and TW Prow2 1 Dermatology Research centre, Princess Alexandra Hospital,
Brisbane, QLD, Australia and 2 Dermatology, Royal Perth Hoospital, Perth, WA, Australia
This study explores the use of a magnetophoretic drug patch in combination with microneedles to
deliver fluorescein through the stratum corneum Microneedles and drug patches have been com-
bined in the field of transdermal drug delivery and this has been coined the “poke and patch” tech-
nique. Microneedles are applied for a few seconds to the skin followed immediately by the appli-
cation of a drug containing patch. Patch delivery of drugs is generally most successful with drugs
of molecular weight less than 500 dalton The patch was applied to ex vivo abdominoplasty skin
immediately following microneedle application .Transepidermal water loss (TEWL) was measured
before and after microneedle insertion. This combination of microneedle and magnetophoretic patch
was compared to drug delivery after microneedle insertion alone and compared to microneedle
insertion followed by application of a passive,non magnetic patch . The substance chosen to assess
transdermal delivery was sodium fluorescein, molecular weight 376. Penetration of fluorescein
was assessed first with dermatosopic images to localise microneddle pores followed by laser scan-
ning confocal microscopy (LSCM) in fluorescent mode:a z-stack of images were used to quantify
fluorescence intensity and dye positive areas The results show the transdermal delivery of fluores-
cein was significantly increased over the passive control patch and delivery using microneedles
without a patch
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Efficacy of sodium L-ascorbyl-2-phosphate 5% lotion in the treatment of acne vulgaris in
vitro and in vivo 
K Kaneko,1 T Mineo,1 N Kato1 and H Ikeno2 1 Wamiles Cosmetics Inc., Yokohama, Japan and
2 Ikeno Clinic, Tokyo, Japan
We recently conducted an open label clinical study and an in vitro study on inflammatory cytokine
index, by using a preparation which contains 5% sodium L-ascorbyl-2-phosphate (APS) in com-
monly used general lotion, in order to research efficacy in the treatment of acne vulgaris (acne). In
the open label clinical study, patients (17 to 32 years of age) with moderate acne lesions were
enrolled and randomized to apply either APS 5% lotion (VCL) or placebo lotion (PL). Participating
patients had not used isotretinoin for 6 months, or any other oral or topical agents for the treatment
of acne for 3 months prior to entering the study. Forty-two patients completed the study protocol
(22 in the VCL group and 20 in the PL group). Efficacy and adverse effects were assessed at base-
line, and at weeks 4, 8, and 12, according to the standard assessment method by a specialist. Nei-
ther VCL nor PL group had any remarkable adverse effects. In the global improvement assessment,
the percentage of patients in the VCL treatment group showing either good or excellent improve-
ment was 77.3% (p<0.05) compared with 25% in the PL treatment group. In the inflammatory
cytokine index study, after incubating for a period of 48 hours at 90-100% confluency, neonatal
human keratinocytes (NHEK(F)) were treated for 4 hours with VCL. Peptidoglycan (PGN) from Staphy-
lococcus aureus at a final concentration of 0.1 mg/mL was then added and cultured further. Inter-
leukin (IL)-8 was measured in order to evaluate anti-inflammatory effects of VCL. Twenty-four hours
after the stimulation with PGN, the amount of IL-8 in the culture supernatant fluid was measured
by ELISA and compared. While treated with VCL, and 24 hours of a PGN-induced stimulation, the
production of IL-8 was significantly inhibited in the culture medium in a dose-dependent manner
(range; 0.63mg/mL - 2.5mg/mL). In addition to our past reports on the in vitro anti-inflammatory
effect, this study suggests clinical efficacy of VCL for the treatment of acne as well as its inhibitory
effect against inflammatory cytokines production.
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Human papillomavirus in non-melanoma skin cancer
S Goolamali,1 N Mladkova,2 K Purdie,2 M de Koning,3 W Quint,3 N Francis,4 N Morar,1 R Meys,1
C Harwood2 and C Bunker1 1 Dermatology, Chelsea and Westminster Hospital, London, United
Kingdom, 2 Centre for Cutaneous Research, Blizard Institute, QMUL, London, United
Kingdom, 3 DDL Diagnostic Laboratory, Rijswijk, Netherlands and 4 Histopathology, ICSM,
London, United Kingdom
HPV has been implicated along with ultraviolet radiation as a co-factor in non-melanoma skin car-
cinogenesis. In an ongoing case/control study we have been studying HPV in pre-cancerous skin
lesions- actinic keratoses (AKs), squamous cell carcinoma (SCC)-in situ (CIS) and penile pre-cancer
(PIN) as well as non-melanoma skin cancer (NMSC)-basal cell carcinoma (BCC) and SCC in HIV
+ve and HIV –ve individuals. We have previously shown high rates of genital HPV types in both
HIV + and HIV –ve non-genital NMSCs, with beta and next cutaneous types the most prevalent in
the HIV +ve group. This work extends our HPV typing of HIV-ve NMSCs. A further 25 lesions from
8 HIV –ve individuals have been studied. DNA has been extracted from microdissected, formalin-
fixed, paraffin-embedded tissue and typed for beta, genital and cutaneous HPV by broad-spectrum,
highly sensitive assays.Total typed to date: 33 HIV –ve patients and 54 lesions (33 BCC, 14 SCC, 1
CIS, 5 AKs, 1 PIN). Genital types were detected in 11/21 (52%) patients +ve for any HPV type (4
BCC, 6 SCC, 2 AK: HPV 6, 16, 18, 52, 74); beta types in 8/21 (38%: 6 BCC, 1 SCC, 2 AK: HPV 8,
15, 22, 23, 24, 25, 36, 76, 80, 92, 93, 96); cutaneous types in 7/21 (33%: 2 BCC, 4 SCC, 1 PIN:
HPV 1, 3, 4, 27, 29). Multiple types were identified in 5/21 (24%) HIV-ve individuals compared
with 5/12 (42%) of HPV +ve/HIV +ve individuals previously reported. In summary, HPV is highly
prevalent in pre-cancerous lesions and NMSC of HIV –ve and HIV +ve patients. Although isolated
from non-genital skin, genital HPV types, including high-risk oncogenic types 16 and 18, are the
most common. Beta types, reportedly the most prevalent HPV type in NMSC, are less common.
Multiple types are less prevalent in the HIV –ve group, possibly reflecting differences in immune
status.
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Several types of clones existed at the same time in a patient with peripheral T-cell lymphoma,
not otherwise specified
D Suzuki,1 K Iwatsuki,2 T Mitchell3 and S Whittaker3 1 Dermatology, Japanese Red Cross
Okayama Hospital, Okayama, Japan, 2 Dermatology, Okayama University Graduate School
of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan and 3 Skin Tumor Unit,
St John’s Institute of Dermatology, Division of Genetics and Molocular Medicine, King’s
Colleage London, London, United Kingdom
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) has heterogeneous clinical histo-
logic immunophenotypic, cytogenetic and molecular features, and it does not correspond to any
of the specifically defined types of mature T-cell lymphomas in the current WHO classification. We
present a case of a patient with PTCL-NOS who had three types of skin lesions. Clinically these
lesions were plaque, tumor and subcutaneous tumor, and their histological findings were similar to
mycosis fungoides, extranodal NK/T-cell lymphoma, nasal type and subcutaneous panniculitis-like
T-cell lymphoma, respectively. Infiltrating tumor cells had CD3+CD4+CD56- phenotype and they
were negative for Epstein-Barr virus. We extracted genomic DNA from three types of lesions and
examined them with PCR-SSCP analysis based on BIOMED-2 methods. Different clonal tumor
cells were detected from each lesion, and one of them had a clonal T cell receptor delta rearrange-
ment. In addition we found three types of lesions repeatedly and they occurred at random. This
result indicated that several types of clonal tumor cells existed at the same time in one patient with
PTCL-NOS and that these different tumor cells made different lesions clinically and histologically.
We suggest heterogeneous features of PTCL-NOS would be caused not only by instability of tumor
cells but also by co-existence of different types of tumor cells.
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The clinical and histological effect of home-use, combination blue-red LED phototherapy for
mild to moderate acne vulgaris in Korean patients: a randomized, controlled trial
H Kwon,1 J Yoon,2 S Park,1 H Ryu,1 B Park,3 Y Kim,3 J Lee,4 J Lee3 and D Suh1 1 Dermatology,
Seoul National University College of Medicine, Seoul, Republic of Korea, 2 Acne Research
Laboratory, Seoul National University Hospital, Seoul, Republic of Korea, 3 Dermatology,
Chonnam National University Medical School, Gwangju, Republic of Korea and 4 Ceragem
Medisys, Cheonan, Republic of Korea
Standard acne medications have demonstrated relatively modest efficacy, but only at the expense
of various side effects and discomforts. Therefore, there is a growing demand for an alternative
treatment modality. This study was designed to determine the clinical and histological effects of the
home-use, combination blue-red LED phototherapy (OCimple Light Therapy System MP 200, CER-
AGEM MEDISYS). A total of 35 patients with mild to moderate acne were randomly assigned to
either blue-red LED device irradiation group or control group using sham device. Patients allocated
to the treatment group were instructed to use LED device, twice per day for 4 weeks, serially receiv-
ing 420 nm blue light (0.91 J/cm2, 2.5 minutes) and 660 nm red light (1.22 J/cm2, 2.5 minutes) per
session. Patients’ follow up was conducted at 2, 4, 8, and 12 weeks after baseline. Skin biopsy was
also performed for immunohistochemical analysis of MMP-9, TNF-α, IL-8, TLR-2, SREBP-1 and
NF-κB. Our study showed that treatment group has shown significant clinical improvement in both
inflammatory and non-inflammatory acne lesions after 2 weeks of treatment compared with con-
trol group, and the clinical efficacy maintained until 12-week follow up. Acne severity evaluated
by both dermatologist and patients’ self-assessments showed the similar patterns, and side effects
were minimal. Histopathologic results were well correlated with clinical results, partly elucidating
molecular mechanisms related with therapeutic effects. Therefore, our data confirm that combina-
tion blue-red LED phototherapy could be an alternative treatment modality for acne with remark-
able efficacy and safety.
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First experience with adalimumab for two variants of linear IgA disease (LAD): classic LAD
and IgA-mediated epidermolysis bullosa acquisita
JL Blok, MF Jonkman and B Horváth Dermatology, University Medical Center Groningen,
Groningen, Netherlands
Linear IgA disease (LAD) is an auto-immune mediated subepidermal blistering disease occurring
on the mucous membranes and the skin. In classic LAD, blistering occurs due to the fact that sev-
eral antigens located above the sublamina densa are targeted by IgA, in which LAD-1 is the most
important antigen. IgA-mediated epidermolysis bullosa acquisita (IgA-EBA) is another subtype of
LAD. In IgA-EBA type VII collagen is targeted by IgA, which is part of the anchoring fibrils that are
located in the sublamina dense zone. Both diseases are frequently resistant to conventional thera-
pies with prednisolone, dapsone and colchicine. We treated two female patients with adalimumab
who were diagnosed with respectively classic LAD and IgA-EBA, and failed on conventional treat-
ment with dapsone. In both patients treatment with dapsone was combined with adalimumab. The
classic LAD patient only mildly improved with 40 mg adalimumab twice weekly, however, pruri-
tus and skin lesions improved significantly after increasing the frequency of administration to once
weekly. Due to the development of an interstitial lung disease that was possibly induced by adali-
mumab, the therapy had to be discontinued. Within several weeks the patient had an exacerbation
of LAD. The second patient, who was diagnosed with IgA-EBA, also had significant improvement
of pruritus during treatment with adalimumab and the number of bullae declined within several
weeks after commencement of adalimumab. However, after 6 months she had a relapse of symp-
toms and adalimumab was discontinued. Currently, her IgA-EBA is relatively stable on treatment
with dapsone, which is periodically combined with prednisolone. These cases illustrate that the
TNF-α inhibitor adalimumab may be effective in both subtypes of LAD when conventional treat-
ment fails. However, studies are needed to determine the role of TNF-α in the pathogenesis of both
subtypes of LAD, the effectiveness of adalimumab and to establish appropriate dosing schedules.
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Hidradenitis Suppurativa: The Effect Of Combinated Treatment With Oral Clindamycin And
Rifampicin
S Zauli, A Borghi, G Toni, M Ricci, S Giari, A Virgili and V Bettoli Department of Clinical and
Experimental Medicine, Section of Dermatology, University of Ferrara, Ferrara, Italy
Hydradenitis Suppurativa (HS) is a chronic disease with exacerbations characterized by inflamma-
tory lesions. Therapeutic approaches to HS may be medical, surgical and/or instrumental. Among
the medical therapies, antibiotics are frequently used to treat HS but few data on their efficacy are
available. The aim of the present study was to assess the efficacy and the tolerability of a 10-week
combination of systemic clindamycin (600 mg daily) and rifampicin (600 mg daily) in the treat-
ment of patients with severe HS. Clindamycin and rifampicin are antimicrobial agents that inhibit
bacterial protein synthesis, but their effects is supposed to be both anti-bacterial and anti-inflam-
matory. The authors have compared the results of their study with the literature data. Twenty patients
affected by severe HS during active inflammatory phase were enrolled in a prospective non com-
parative study. The main parameters used to evaluated the efficacy of the treatment have been Sar-
torius score, assessing the severity of the disease before and after treatment, the number of exacer-
bations during the three months of treatment compared with those occurring in the previous three
months, PGA (patient global assessment) and IGA (investigator global assessment) after treatment.
After 10-weeks of treatment the Sartorius score significantly improved and the number of exacer-
bations was reduced in 19 patients. The two drugs were well tolerated except in one patient who
experienced nausea and vomiting. The antibiotic combination of clindamycin and rifampicin resulted
effective in the treatment of severe HS and well tolerated. The same as it can be seen in literature.
In this study patients were not randomized in a treatment group versus a placebo group for ethical
reasons. This combination was not compared with other treatments because in author’s experience
it is the best option in severe HS in term of efficacy, tolerability, quick onset of action and the cost.
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Very low electromagnetic field and innate immunity in HaCaT cells
M Auriemma,1 G Vianale,2 C D’Angelo,2 E Costantini,2 M Reale2 and P Amerio1 1 Dermatologic
Department, G. d’Annunzio University, Chieti, Italy and 2 Department of Oncology and
Experimental Medicine, G. d’Annunzio University, Chieti, Italy
Defensins (DF) comprises a large group of host defence peptides. In recent years, the functions of
DF as immunomodulatory and tissue repair agents have been widely investigated. Several evidences
exists that electromagnetic fields (EMF) can influence both inflammatory processes andrepair mech-
anisms on different tissue models. To study the effect of extremely low frequency EMF (ELF-EMF) on
Anti Microbial Peptides components of the human innate immune system, human keratinocyte cell
line (HaCaT) was exposed at 1 mT, 50 Hz and compared with unexposed cells at different time
points (2, 18, 36 hours). Cytokines and DF gene expression profile were analyzed by polymerase
chain reaction. Our preliminary results show that IL-1β and IL-10 cytokine expression were upreg-
ulate after 2 hours of ELF-EMF exposure. However while IL-1β expression was not significantly influ-
enced by 18 and 36 hours of continuous exposure, IL-10 expression was increased after 18h and
returned to normal levels after 36 hours. Interestingly human beta defensin (HBD) 2 and 3 are unreg-
ulated after 2h of ELF-EMF exposure. Meanwhile, only HBD-2 was sensibly decreased after 18h,
with no significant variation observed at 36h. No differences were observed in HBD-3 expression
at 18 and 36h. Simultaneously ELF-EMF does not seem to influence Vitamin D Receptor (VDR)
expression in all investigated time points. These preliminary results may show that ELF-EMF mod-
ulates cytokines expression in HaCaT cells. The upregulation of IL-1β could be responsible for the
induction of HBD-2 and HBD-3. This could explain how ELF-EMF acts on tissue repair, at least in
part, enhancing DF expression through a different pathway than VDR activation. More experiments
are needed to better elucidate the actual molecular mechanism that induces the relative immuno-
suppression and tissue repair enhancement determined by ELF-EMF
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Oral Supplementation of Omega-3 as an adjunct in the Treatment of Psoriasis
CR Sgarbi, RT Villa and M Franco Souza Marques Foundation, São Paulo, Brazil
One of the mechanisms that induce inflammation in psoriasis depends on cycloxygenase 2 enzyme
activity. This enzyme is produced during the inflammatory response and acts on polyunsaturated
fatty acids, leading to formation of cell signaling molecules, like prostaglandins, thromboxanes,
leukotrienes. When cycloxygenase 2 acts on arachidonic acid, which is an omega-6 fatty acid, it
produces prostaglandins E2, with pro inflammatory and proliferative action in most tissues. How-
ever, when there is a bigger contribution of omega-3 essential fatty acids, specially eicosapentaenoic
acid and docosapentaenoic acid, they become the main substrates of the enzymatic reaction, pro-
ducing eicosanoids without inflammatory activity. The purpose of this study is to demonstrate the
effects of phospholipids rich in omega-3 polyunsaturated fatty acids in psoriasis, through objective
analyzes of PASI and BSA reduction. Thirty patients between 28 and 70 years of age were evalu-
ated with psoriasis vulgaris. PASI and BSA were calculated, and photographic register was made at
the beginning and after 60 days of treatment using 400 mg daily of phospholipids rich in omega-3
polyunsaturated fatty acids. Mean reduction in PASI was 52%. It was expressed, specially, by the
reduction of the erythema and the infiltration. The BSA reduction was less pronounced (41%). In
addition, there was important reduction of the subjective symptoms reported by patients, mainly
itching. This study shows that omega-3 polyunsaturated fatty acids administration, reducing the pro-
porcion of omega-6/omega-3, can divert the enzymatic activity of cycloxygenase 2 for the main
degradation of omega-3 fatty acids, producing eicosanoids without inflammatory activity and, con-
sequently, reducing the inflammatory manifestations. It is assumed that this is only an adjunct ther-
apeutic modality, with the purpose of adding benefits to the already established treatments of the
disease.
353
Clinical features and course of Pemphigus
C Ülker,1 A Akman-Karakas,1 ÖZGüR Tosun,2 S Uzun1 and E Alpsoy1 1 Akdeniz University
School of Medicine Department of Dermatology and Venerology, Antalya, Turkey and 2
Akdeniz University School of Medicine Department of Biostatistics, Antalya, Turkey
Many factors affect the clinical course of pemphigus. At this study, we aimed to investigate the effects
of factors other than the ones reported at literature, such as delay at diagnosis, compliance to fol-
low-ups, treatment protocols, site of lesion and site of lesion resistant to treatment, on clinical course
of pemphigus. A total of 61 pemphigus patients (mean age=53.03±13.86; F/M=1.2/1; follow-up
duration =37.7±32.2 months) who were followed at our clinics between the years 2005 and 2010,
diagnosed by DIF, IIF and ELISA methods besides histopathological evaluation. A positive correla-
tion was found between the decrease of the PDAI at the beginning and last visit of the treatment
and compliance to follow-ups (r=0.53, p=0.01). It was observed that at patients who had an oral
lesion as the onset lesion, recurrences and treatment-resistant lesions occurred mostly at mouth
(p=0.01). At patients with PF, it was detected that patients who had onset lesions on their bodies
had resistant lesions on their bodies as well (p=0.02). It was demonstrated that intralesional CS treat-
ment added to CS treatment provided a decrease at VAS and oral PDAI scores, compared to CS treat-
ment alone (p=0.03, p=0.03). It was observed that treatment-related side effects were more frequent
at CS treatment. Besides osteoporosis was related to duration of CS use (p=0.01). It was observed
that familial history of DM and high BMI increased the risk fo treatment-related DM (p=0.03, (p=0.04).
It was considered that compliance to follow-ups may positively affect clinical course. It must be
considered that treatment-resistant lesions and recurrences occur mostly at onset site of disease.
Intralesional CS may be recommended additional to systemical CS, especially at treatment of oral
lesions. The relation of osteoporosis development with duration of CS use, and DM development
with familial DM history and BMI should be warning for detection and prevention of side effects.
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Psychological factors in chronic urticaria – preliminary results
A Ograczyk and A Zalewska-Janowska Psychodermatology Department, Medical University of
Lodz, Lodz, Poland
Chronic urticaria is regarded as psychodermatological condition - stress could cause or exacerbate
skin lesions, but also the disease could be a source of stress and exerts negative impact on patients’
quality of life (QoL).The aim of the study was to evaluate the relation between psychological fac-
tors, itch and chronic urticaria patients QoL. 13 chronic urticaria patients participated in the study
(11 females, 2 males; age range: 37-68 years; mean+/-SD 51.62+/-11.26). Duration of the disease
ranged from 6 months to 10 years; mean+/-SD 3 years+/-3,21 months. Disease severity was esti-
mated by Visual Analog Scale (VAS) in patients’ evaluation. It ranged from 0 to 9.7 (mean+/-SD
4.15+/-3.20). Itch was examined by Itch Severity Evaluation Questionnaire (Szepietowski, Reich,
2010) and ranged from 3 to 15 (mean+/-SD 4.15+/-3.20). The patients completed set of following
questionnaires (all validated in Polish): Hospital Anxiety and Depression Scale (HADS, Zigmond,
Snaith), Sense of Coherence (SOC-29, Antonovsky), Social Readjustement Rating Scale (SRRS,
Holmes, Rahe), Perceived Stress Scale (PSS-10, Cohen, Kamarck, Mermelstein) and Dermatology
Life Quality Index (DLQI, Finlay, Khan). Pearson correlation coefficient (r) was assessed and the sta-
tistical significance was set at p<0.05. The relation between itch and depression score was noted –
the more intensive itch, the higher depression level was manifested (r=0.88). The stress level (VAS)
correlated negatively with SOC subscale resourcefulness – ones who were more stressed reported
lower ability to cope with difficult situations (r=-0.88). Negative association between stress level
(VAS) and stressful life events was discovered–patients who declared being more stressed experi-
enced less difficult situations to cope with (r= -0.88). Itch could significantly influence chronic
urticaria patients’ mood, so it is important to take it into account in all analyses. The results indi-
cated that there could not be a direct connection between stressful life events occurrence and high
stress level – coping with stress could be an essential intermediary factor.
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Comparison between TCA peels versus Erbium:YAG Laser in the treatment of Xanthelasma
A Kotb and M Abdel-Hamid Dermatology, National research center, Cairo, Egypt
Introduction & Objectives: Xanthelasma palpebrarum is one of the cosmetically disturbing lesions
affecting periocular region. It affects all age groups but most commonly middle aged females.
Many treatment modalities have been used as: CO2 & Er:YAG lasers, surgical removal, chemical
substances application as phenol & TCA (trichloroacetic acid). Material & Methods: In this clinical
trial, 19 middle aged females suffering from macular & flat xanthelasma palpebrarum were included.
Our aim was to evaluate the effect of different TCA concentrations (35%, 50% & 80%) on xanthe-
lasma & compare it with the results of Er:YAG laser. The patients were divided into 4 groups, three
groups with 5 patients each. The 1st group was treated with TCA 35%, 2nd group was treated with
TCA 50% and the 3rd group with TCA 80%. The 4th group consists of 4 patients treated with Er:Yag
laser. Results: The 1st group showed mild unsatisfactory results following 3 sessions with 2 weeks
spacing between sessions, a fourth session with TCA 50% was applied to 1st group after which com-
plete disappearance of lesions occurred. The 2nd group showed partial improvement after 2 ses-
sions with complete disappearance of lesions after 3rd session. The 3rd group had great results
from the 1st session and only 2 patients out of 4 patients needed a 2nd session with TCA 80%. The
4th group showed complete cure after 2 sessions of Er:YAG. The most common complication of TCA
application was mild inflammation which subsided in less than 18 hours after the session. Another
problem which occurred in 6 patients was the black colored scales which was formed after 30 hours
& totally removed after about 72 hours. Only one patient of the TCA 80% group experienced hypopig-
mentation. On the other hand, the entire 4th group experienced a painful burning sensation durig
the session & reddness & slight scaling shortly after the sessions. Conclusions: Finally, I think TCA
50% & 80% are effective & cheap treatment of flat & macular xanthelasma. ER:YAG Lasers are also
effective but very expensive & associated also with the risk of recurrence.
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Ultrasonography reveals nail thickening in patients with chronic plaque psoriasis
P Gisondi, L Idolazzi and G Girolomoni University of Verona, Verona, Italy
Background: Nail psoriasis is usually investigated and diagnosed by clinical examination. Ultra-
sonography is a non-invasive imaging technique for studying soft tissue involvement. Objective:
Estimating nail involvement in patients with chronic plaque psoriasis by ultrasonography. Methods:
Prevalence, clinical type and severity of nail involvement according to nail psoriasis and severity
index (NAPSI) was investigated in 138 patients with psoriasis. The thickness of the plate and bed of
the fingernails were measured in 54 patients with psoriasis, 46 healthy controls and 37 patients with
chronic eczema, using an ultrasonographic system equipped with a frequency transducer of 18
MHz. Results: The prevalence of nail psoriasis was 73% (102 out of 138). Onycholysis and thick-
ening of the nail plate were the most common clinical type affecting 56% and 50% of patients,
respectively; splinter haemorrhages was the less common involving 10% of patients. The mean
NAPSI score was 18.4 ± 17.5 (SD; range 0-107). The thickness of fingernail plate and bed was sig-
nificantly higher in patients with psoriasis with nail disease compared to healthy controls and patients
with chronic eczema (p<0.001). There was a linear correlation between NAPSI and plate and bed
nail thickness (r=0.52 and r=0.38, p=0.001). Increased nail plate and bed thickness was observed
also in patients with psoriasis without clinically apparent nail involvement. Conclusions: Thicken-
ing of the nail is a common feature of nail psoriasis also in patients without clinically apparent nail
involvement.
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Antibiotic susceptibility of genital Ureaplasma urealyticum and Mycoplasma hominis
J Zabarauskaite,2 J Kersyte,1 O Lapteva,1 A Paskevicius,3 I Buckute Butkeviciute2 and M Bylaite2 1
Clinic of Infectious and Chest Diseases, Dermatovenereology and Allergology, Vilnius
University, Vilnius, Lithuania, 2 Centre of Dermatovenereology, Vilnius University Hospital
Santariškiu Klinikos, Vilnius, Lithuania and 3 Laboratory of Microbiology, Centre of Laboratory
Diagnostics, Vilnius University Hospital Santariškiu Klinikos, Vilnius, Lithuania
To determine antibiotic susceptibility of female genital U.urealyticum and M.hominis in the Cen-
tre of Dermatovenereology in 2010. To analyse retrospectively all female visits to the Centre for STI
in 2010 and whom the cultures for U.urealyticum and M.hominis were performed. Antimicrobial
susceptibility to macrolides, clindamycin, tetracyclines, fluoroquinolones was determined. 1058
females visited the Centre for STI in 2010. Out of 122 cultures 61 were positive: 53 -for U.ure-
alyticum, 7 -for both bacteria, 1 -only for M.hominis. U.urealyticum susceptibility to erythromycin,
clarithromycin, azithromycin, clindamycin, doxycycline, tetracycline, pefloxacin, ofloxacin, minocy-
cline was 88.7%, 49.1%, 92.5%, 81.1%, 88,7%, 83%, 83%, 41.5%, 86.8% respectively. Mixed
infection cultures showed the highest resistance to azithromycin (85.7%), clarithromycin (85.7%),
erithromycin (71.4%), the highest susceptibility (71.4%) -to clindamycin, doxycycline, tetracycline.
Kendall’s Tau-b coefficients showed significant relations between resistance to azithromycin and
doxycycline, erythromycin and clindamycin in cultures of U.urealyticum. The resistance to pefloxacin
presumed resistance to tetracycline. In most cases U.urealyticum was detected as single pathogen
most susceptible to azithromycin, while erythromycin, doxycycline could be a 2nd choice drugs.
Clarithromycin, ofloxacin were least effective. In mixed infection the highest susceptibility was to
clindamycin, doxycycline, tetracycline. In cultures of U.urealyticum relations were found between
resistance to azithromycin and doxycycline, erythromycin and clindamycin. Resistance to pefloxacin
is related to the resistance to tetracycline.
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Xanthoma Disseminatum, a rare non–Langerhans cell histiocytic syndrome
V Mouziouras, N Stampolidis, G Karagkounis, I Stasinopoulos, P Kourakos, I Irini Mavromati,
T Argyrakos, D Rontogianni and O Castana Plastic and Reconstructive Surgery, General
Hospital “o Evangelismos”, Athens, Greece
This work raises questions about monitoring and treatment of xanthoma disseminatum (XD), a rare
non–Langerhans cell histiocytic syndrome. The non-Langerhans Cell Histiocytoses (non- LCH) is a
disease entity presenting lesions in various organs as well as diffuse skin lesions. XD typically involves
the skin, particularly the flexor skin folds and eyelids. Clinically it can be divided into three groups,
those that predominantly affect skin, those that affect skin but have a major systemic component,
and those that primarily involve extracutaneous sites, although skin may be involved. The disease
often begins insidiously but may lead to extensive morbidity and mortality. No familial cases have
been reported while the disease is more prevalent among males. This chronic disease has not known
established treatment. XD is a rare non–Langerhans cell histiocytic syndrome that predominantly
affects young men and seems to be sporadic. The symptomatic lesions may be cured by surgery, the
role of radiotherapy and chemotherapy is unconfirmed. We present the case of a 43-year-old white
man, in excellent health status, who had in our department during the period of last two years twenty
nine periorbital and three at the area of trunk atypical xanthogranulomas excised. Lastly he appeared
with diffuse red or brownish papules and nodules on his armpits and back. The biopsy specimen
revealed non–Langerhans cell histiocytosis confirmed by immunohistochemical studies. On XD
clinical presentation depends at different stages of maturation of the precursor cell. Meticulous fol-
low up of the patient is mandatory in order to promptly control skin damage and to reveal future
involvement of extracutaneus sites. Radiotherapy, Chemotherapeutic agents and steroids have a role
in palliating local symptoms but their objective response to the control of disease stabilization is
unconfirmed since the response to any form of therapy has been unsatisfactory.
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Indigo naturalis up-regulates claudin-1 expression in cultured human keratinocytes and pso-
riatic lesions
Y Lin1 and T Hwang2 1 Chang Gung Memorial Hospital, Keelung, Taiwan and 2 Chang Gung
University, Taoyuan, Taiwan
The use of indigo naturalis to treat psoriasis has proved effective in our previous clinical studies. To
investigate the effect of indigo naturalis on claudin-1 expression in cultured human keratinocytes
and psoriatic lesions. The expression of claudin-1 was analyzed in cultured primary human ker-
atinocytes (PHK) by fluorescent immunostaining, real-time RT-PCR and Western blot analysis. The
effect of indigo naturalis on tight junction (TJ) function was measured by transepithelial electrical
resistance (TEER) and paracellular tracer flux. Claudin-1 expression in psoriatic plaque with or with-
out indigo naturalis treatment was analyzed by immunohistochemical method. Effects of indigo,
indirubin, and tryptanthrin, three major components identified in indigo naturalis, on the TJ func-
tion were also studied. Indigo naturalis, at non-cytotoxic concentrations, enhanced the expression
of claudin-1 in cultured PHK which were validated at the mRNA and protein levels with dose-
dependence. Indigo naturalis increased activity of protein kinase C (PKC) in PHK; and indigo nat-
uralis-induced claudin-1 expression was inhibited by a PKC inhibitor. The increase of TEER and
reduction of permeability of the 4 kDa FITC-dextran in indigo naturalis-treated keratinocytes were
further demonstrated. The three major components of indigo naturalis synergistically exerted effects
on up-regulating TJ function with indirubin accounting for the majority of the effect. Notably, the
restoration of claudin-1 was observed in healed psoriatic lesions after indigo naturalis treatment as
compared with the unhealed psoriatic lesions treated by vehicle. Collectively, these data suggest
that indigo naturalis could up-regulate claudin-1 expression in cultured PHK and indirubin provide
the major contribution. Indigo naturalis may help restore skin TJ function when used in treating
psoriasis.
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A Novel Fluorescent Assay Used to Measure the Absorption Efficacy of a Sonic Applicator
G Peterson, E Henes, K Ortblad, M Kearney, L Tadlock and R Akridge Clinical Research, L’Oreal
- Clarisonic, Redmond, WA
Eye serums/creams are typically applied to the delicate skin around the eye area using a gentle tap-
ping motion of the ring finger. A sonic applicator was invented to replace manual application by
generating gentle sonic pulses that rapidly (but gently) massages serums/eye creams into outer most
layers of the stratum corneum. In order to determine the efficacy of this technology a novel fluo-
rescent serum-dye assay was developed to assess the efficacy of sonic application. A single visit
study was conducted to assessed absorption by different application methods. In this study a non-
invasive fluorescent serum-dye method, as well as photographs, and image analysis were utilized.
A fluorescent marker (cosmetic ingredient oxyresveratrol) was mixed into an anti-aging sea serum
(final mixture 0.1% oxyresveratrol) and applied to the lower eye area, both manually and with the
sonic applicator. The same volume of the serum-dye mixture (≈50μl) was applied to lower area of
both eyes. Participants were instructed to apply the serum-dye mixture to the right lower eye area
using their ring finger as they normally would at home, and to the left lower eye area using the
sonic applicator. Immediately after application, the serum-dye mixture was blotted twice with an
absorbent tissue in a consistent and systematic way to remove excess serum remaining on the sur-
face of the skin. Photographs were taken using a Visia CR camera. Ultraviolet images revealed a
disproportional amount of fluorescent marker remaining on the sonically applied eye area. The flu-
orescence remaining around the eye area after application was quantified by using image analysis
software [Image J 1.43; NIH]. Results were then compared statistically using a paired t-test. A sta-
tistically significant difference (p=0.003) was detected between the manual and sonic application.
Photographs and Image J analysis confirm that sonic application using a fluorescent marker results
in more absorption into the outer most layers of the stratum corneum than manual application.
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Evaluation of a Novel Sonic Brush Head to Deeply Cleanse Pores
L Tadlock, E Henes, K Ortblad, M Kearney, N Koski and R Akridge Clinical Reserach, L’Oreal -
Clarisonic, redmond, WA
The purpose of this study was to evaluate the efficacy of a newly designed deep pore (DP) cleans-
ing brush head in conjunction with a handheld battery operated sonic skin care brush. The convex
surfaces formed from the nasal folds of the nose often have large deep pores and are considered
areas on the face that are difficult to cleanse. Using a newly developed fluorescent microsphere
assay the pores on the sides of the nose were used to assess the efficacy of the DP cleansing sonic
brush head A single visit, split nose (n=20), randomized study was conducted using a non-invasive
fluorescent microsphere assay, photographs, and image analyses. In the fluorescent microsphere
assay a mixture of black polyethylene (27 - 45μm) and fluorescent yellow (20 – 27 μm) microspheres
were used to label the pores. A 1 to 1mixture of microspheres was applied on the left and right
sides of the nose in such a manner as to fill the pores with microspheres. Any loosely adhered micros-
pheres were removed using damp gauze. A randomization schedule identified the cleansing method
per side of the nose. Each side of the nose was cleansed simultaneously with the identified cleans-
ing method and a soap/water mixture. After cleansing the remaining soap/water mixture was removed
using damp gauze. Photographs were taken before and after cleansing. The fluorescent microspheres
remaining in the hard to reach areas (creases) of the nose after cleansing were quantified by using
image analysis software [Image J 1.43; NIH]. The side of the nose cleansed with the DP cleansing
brush head had significantly less fluorescence in pores (955 pixels) compared to manual cleansing
(3410 pixels). Results were compared statistically using a paired t-test. A statistically significant dif-
ference (p=0.0004) was detected in deep pore cleansing efficacy between the new sonic brush head
and manual cleansing. Analysis confirmed that the new sonic brush head is superior in deep pore
cleansing and removed significantly more microspheres from hard to reach areas of the nose (creases)
than manual cleansing.
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Tattoos in the emotional perspective
B Antoszewski,1 A Ograczyk,2 E Wozniak1 and A Zalewska-Janowska2 1 Plastic, Reconstruction
and Esthetic Surgery Department, Medical University of Lodz, Lodz, Poland and 2
Psychodermatology Department, Medical University of Lodz, Lodz, Poland
Nowadays tattoos become more and more popular. By people tattooing their body, they are con-
sidered to be not only a cosmetic skin adornment but also the way of one’s emotional expression.
The aim of the study was to evaluate different emotional aspects (emotional intelligence, control of
emotions such as anger, anxiety and depression) and sense of self-efficacy in people with tattoos.
The research group consisted of 32 people with tattoos (14 females, 18 males; age range: 18-40
years; mean+/-SD 26.84+/-5.69; tattoo number range: 1-24; mean+/-SD 5.68+/-6.73). Every patient
completed set of psychological questionnaires: Emotional Intelligence Questionnaire INTE (Schutte,
Malouff, Hall, et al; Polish adaptation Ciechanowicz, Jaworowska, Matczak), Courtauld Emotional
Control Scale (CECS, Watson, Greer; Polish adaptation Juczynski), The General Self-Efficacy
Scale(GSES, Schwarzer, Jerusalem; Polish adaptation Juczynski). Pearson correlation coefficient (r)
was assessed and the statistical significance was set at p<0.05. Most respondents (78.1%) reported
that their motivation to do tattoo was their personality expression.There were found no statistically
significant difference in emotional intelligence, emotions’ control and sense of self efficacy depend-
ing on respondents’ sex, age and tattoo number. There was observed connection between general
emotional intelligence (r=0.75), its elements (ability to recognize emotions (r=0.62), ability to reg-
ulate emotions (r=0.51) and ability to use emotions to support thinking and performing (r=0.31))
and self-efficacy. The conducted study indicated the relation between emotional intelligence and
self-efficacy (treated as the personal resource to cope with stress), which could be the proof of emo-
tional intelligence significance in adaptive functioning. It seems to be also interesting to extend the
research by comparing obtained results with control group consisting of people without tattoos.
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Evaluation of the effects of anticellulite therapy with the use of radio frequency (RF) moni-
tored by high-frequency ultrasound
KR Mlosek,1 S Malinowska2 and R Debowska3 1 Department of Diagnostic Imaging, II Medical
Faculty of the Medical University of Warsaw, Warsaw, Poland, 2 Life- beauty –private partner,
Grodzisk Mazowiecki, Poland and 3 Dr Irena Eris Centre for Science and Research, Dr Irena
Eris Cosmetic Laboratories, Warsaw, Poland
Cellulite, defined as tissue fibrosis, is a cosmetic defect that affects more than 80% of women and,
unfortunately, is unaccepted by most of them which negatively affects their quality of life. Given
the size of the phenomenon we are continuously looking for effective ways to reduce cellulite.
Reliable monitoring of anti-cellulite treatment remains a problem. The purpose of this study was to
evaluate the effectiveness of cellulite treatments carried using tripolar radio waves monitored by
means of high frequency ultrasound. 39 women, age 23-52 years, were diagnosed with cellulite.
All women underwent 10 treatments with the use of RF. The course of therapy was monitored by
high-frequency tests. Ultrasound with the mechanical head of frequency 50 MHz was used. Ultra-
sound studies examined the following parameters: thickness of the epidermis, dermis thickness,
echogenicity of the dermis, the length and surface area of bands of subcutaneous tissue growth in
the dermis. Thigh circumference, weight and cellulite stage were also rated (Nürnberger-Müller scale
and photonumeric cellulite severity scale) As a result of treatment cellulite reduction occurred in
84.56% of women. Statistically significant decrease in length and area of subcutaneous tissue bands
growing into the dermis and increase of echogenicity of the dermis were observed, which is the
evidence for the increase in the number of collagen fibers. Cellulite reduction was also confirmed
by palpation examination. In conclusion, radiofrequency enables cellulite reduction. A useful aspect
is proper monitoring of the progress of such therapy, which high-frequency ultrasound allows.
364
Treatment of Lentigo Seniles Using Q-switched Ruby Laser and Q-switched Nd:YAG Laser
N Sato and J Nakayama Dermatology, Fukuoka University, Fukuoka, Japan
We treated lentigo seniles using Q-switched ruby laser in combination with Q-switched Nd:YAG
laser for better therapeutic outcomes. Post inflammatory hyperpigmentation occured after Q-switched
ruby laser irradiation for lentigo seniles, was clearly reduced when we irradiated several times with
Q-switched Nd:YAG laser with a wavelength of 1064nm and the energy fluence 2.0 -2.5J/cm2, the
pulse width of 5-20ns, 6mm spot size, and repetition rate of 5-10 Hz there after. On the other hand,
irradiation with Q-switched Nd:YAG laser with the same power on the lesions of the face entirely
as a pretreatment reduced the risk of post inflammatory hyperpigmentation after spotty irradiation
with Q-switched ruby laser for lentigo seniles. There was no scarring, textual changes or hypopig-
mentation. The treatment of lentigo seniles using Q-switched ruby laser in combination with Q-
switched Nd:YAG laser was found to be excellent therapy.
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Long-term Efficacy and Safety of a Novel Sonic Brush Head to Deeply Cleanse Difficult Areas
of the Face
K Ortblad, E Henes, L Tadlock and R Akridge Clinical Researach, L’Oreal - Clarisonic, Redmond,
WA
A new deep pore cleansing brush head using sonic technology was developed to cleanse difficult
to reach areas of the face (deep pores, around the nose, base of wrinkles). Long-term efficacy and
safety of the deep pore cleansing brush head was evaluated on a population who were currently
using sonic technology for facial cleansing. Efficacy was evaluated in an 8 week, 3-visit home use
study (n=55) using questionnaire data & before/after use photographs. Safety/gentleness was eval-
uated in a second randomized study (n=10) using an exfoliation tanning methodology on the lower
leg. Transepidermal Water Loss (TEWL), Melanin (M), Skin Moisture/Hydration (H) & Erythema (E)
were assessed with the tanning method; before/after 1 minute exaggerated use in a 2”x2” area for
each of the 3 test products [sonic skin care brush using a normal brush head, deep pore cleansing
brush head, a nylon facial cleansing pad], as well as a non-treatment control. Duplicate measure-
ments of M, H, E & triplicate measurements of TEWL were taken before/after treatment After 8 weeks
of home use 88% of subjects preferred the new deep pore cleansing brush head to the sonic brush
head they were previously using, & perceived the deep pore cleansing brush head cleansed better
overall (81%), improved the clarity of their skin (81%), & provided a deep pore cleansing (93%).
Parametric statistical methods were used to evaluate the safety/gentleness. TEWL measurements after
product use fell within the normal range previously established for skin on the lower leg. The aver-
age TEWL for the face & lower leg are similar. Little change in M or E was observed following
excessive use. Final post treatment measurements of H were higher than untreated control for both
the normal & deep pore cleansing sonic brush heads. There was a statistically significantly increase
in H post treatment from the control (p=0.02) for the deep pore cleansing brush head. Analysis
confirmed the new deep pore cleansing brush head is safe/gentle for daily use & cleanses difficult
to reach areas of the face.
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Mozart’s Music Effect on Dehydroepiandrosterone-Sulphate in Dermatological in-Patients
O Heringa, M Kozlowska, A Ograczyk and A Zalewska Psychodermatology, Medical University,
Lodz, Poland
The purpose of this study was to evaluate the effect of Mozart music on selected physiological and
psychological stress parameters in skin diseased in-patients. In dermatological in-patients, physio-
logical and psychological sets of measurements were performed twice (before Mozart listening and
after). Saliva samples measuring Dehydroepiandrosterone-Sulphate (DHEA-S) levels (ELISA) were
collected. In total, six samples were taken from each patient, before Mozart listening and after. Sam-
ples were collected at three different time points during three days (morning, afternoon, evening).
Furthermore, psychological questionnaires measuring mood (University of Wales Mood Adjective
Checklist), depression (Beck’s Depression Inventory), stress (Rahe and Holmes Scale), and behav-
ior (Formal Characteristics of Behavior – Temperament Inventory) were employed. Based on saliva
measurements, a strong tendency was found between the last measurements of both groups (before
and after Mozart; p= 0.054), and a statistically significant difference between the first and last
measurement of the Mozart group (p=0.021) was found. Additionally, patients presented weaker
depression symptoms after listening to Mozart (p= 0.089; strong tendency). Furthermore, we observed
increased saliva DHEA-S levels after three experimental days. In conclusion, listening to Mozart
might be beneficial for chronic skin patients, and might be useful as adjunct to pharmacotherapy.
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Assessing efficacy and safety of a novel sonic applicator after long term home use
R Akridge, G Peterson, K Ortblad, L Tadlock and R Akridge Clinical Reserach, L’Oreal -
Clarisonic, Redmond, WA
A new sonic applicator (SA) to apply eye serums/creams to the delicate under eye area simulating
the gentle tapping motion of the ring finger has been invented. The SA generates gentle sonic pulses
that rapidly (but gently) applies eye serums/creams to outer most layers of the stratum corneum. The
purpose of the study was to clinically assess efficacy & safety via measurements of skin hydration,
elasticity, user perception (questionnaire), & before/after use photographs over 12 wks. A 3-visit,
randomized (anti-aging sea serum, Pro RT3 serum) study with women between the age of 35 - 60
(n=55) with visible signs of aging was conducted. At baseline, the study examiner used the SA to
apply the randomized serum to the left under eye area for 30 seconds. Subjects used the SA to
apply the serum to the right under eye area for 30 seconds. Skin hydration [(H) Corneometer] was
measured at baseline (before & 15 minutes after product use). Skin elasticity [(E) Cutometer] was
measured at the baseline, 4 & 12 week study visits. Photographs & completion of a questionnaire
at each study visit were obtained to assess efficacy & safety. Subjects were instructed to use the
SA/study serum at home twice/day (morning/bedtime). Results for each time point were compared
statistically using a paired t-test. A statistically significant increase (p<0.001) in H was measured
after 15 minutes of use for both serums & majority of subjects perceived their skin was more hydrated
in areas where the serum was applied (95%: anti-aging sea serum; 90%: Pro RT3 serum). After 12
weeks a statistically significant increase (p<0.01) in both gross & net E was measured after use of
the SA with both the serums. Majority of subjects perceived their skin had more elasticity or firm-
ness in areas where the serum was applied with the SA (84%: anti-aging sea serum; 88%: Pro RT3
serum). Safety results were confirmed by a separated study conducted by an independent Derma-
tologist and Ophthalmologist. The study confirmed the SA was clinically effective and safe to apply
eye serums/creams to the delicate under area
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